UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period endedMarch 31, 2019September 30, 2021

OR

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period fromto

Commission file number: 000–26495000-26495

 

CYREN LTD.

(Exact name of Registrant as specified in its charter)

 

Israel Not applicable
IsraelNot applicable
(State or other jurisdiction of(I.R.S. Employer
incorporation or organization)Identification No.)

 

10 Ha-Menofim St., 5th Floor 
Herzliya, Israel4672561
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code 011–972–9–863–6888

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Ordinary Shares, par value ILS 0.15 per shareCYRNNasdaq Capital Market

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x  No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer¨Accelerated filer¨
Non-Accelerated filerSmaller reporting company
  Emerging growth company¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes☐Yes ☐  No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Ordinary Shares, par value ILS 0.15 per shareCYRNNasdaq Capital Market

Indicate the number of shares outstanding of each issuer’s classes of common stock, as of the latest practicable date: 54,465,35790,363,745 ordinary shares as of April 30, 2019.October 31, 2021.

 

 

Table of Contents

 

 Page
PART I – FINANCIAL INFORMATION
   
Item 1.Financial Statements
 Consolidated Balance Sheets as of March 31, 2019September 30, 2021 (unaudited) and December 31, 201820202
 Consolidated Statements of Operations (unaudited) for the three and nine months ended March 31, 2019September 30, 2021 and 201820204
 Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended March 31, 2019September 30, 2021 and 201820205
 Consolidated Statement of Changes in Shareholders’ Equity (unaudited) for the three and nine months ended March 31, 2019September 30, 2021 and 20206
 Consolidated Statements of Cash Flows (unaudited) for the threenine months ended March 31, 2019September 30, 2021 and 2018202078
 Notes to Consolidated Financial Statements (unaudited)910
Item 2.Management'sManagement’s Discussion and Analysis of Financial Condition and Results of Operations2124
Item 3.Quantitative and Qualitative Disclosures About Market Risk2834
Item 4.Controls and Procedures3037
 
PART II – OTHER INFORMATION 
 
Item 6.Exhibits3038
 
SIGNATURES3139

 

i

 

 

CYREN LTD.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF MARCH 31, 2019SEPTEMBER 30, 2021

 

($USD in thousands, except share and per share amounts)

(Unaudited)

 

 Page
  
PART I – FINANCIAL INFORMATION 
  
ITEM 1. Financial Statements (Unaudited)2
  
Condensed Consolidated Balance Sheets2
  
Condensed Consolidated Statements of Operations4
  
Condensed Consolidated Statements of Comprehensive Loss5
  
Condensed Consolidated Statement of Changes in Shareholders’ Equity6
  
Condensed Consolidated Statements of Cash Flows78
  
Notes to Condensed Consolidated Financial Statements910

 

- 1 -

-1-

 

 

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

 

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

($USD in thousands, except share and per share amounts)

  September 30,  December 31, 
  2021  2020 
  Unaudited    
ASSETS      
       
CURRENT ASSETS:      
Cash and cash equivalents $17,932  $9,296 
Trade receivables (net of allowances for credit losses of $77 and $201, as of September 30, 2021 and December 31, 2020, respectively)  3,824   960 
Deferred commissions  932   980 
Prepaid expenses and other receivables  1,653   779 
         
Total current assets  24,341   12,015 
         
LONG-TERM ASSETS:        
Long-term deferred commissions  939   1,125 
Long-term lease deposits and prepaids  780   937 
Operating lease right-of-use assets  9,431   10,900 
Severance pay fund  880   745 
Property and equipment, net  2,728   3,948 
Intangible assets, net  5,753   7,797 
Goodwill  20,689   21,476 
         
Total long-term assets  41,200   46,928 
         
Total assets $65,541  $58,943 

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

-2-

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

($USD in thousands, except share and per share amounts)

  September 30,  December 31, 
  2021  2020 
  Unaudited    
LIABILITIES AND SHAREHOLDERS’ EQUITY      
       
CURRENT LIABILITIES:      
Trade payables $903  $799 
Convertible notes (related party)  10,000   10,000 
Employees and payroll accruals  3,943   3,813 
Accrued expenses and other liabilities ($176 and $37 attributable to related parties, respectively)  1,362   1,420 
Operating lease liabilities  1,638   1,983 
Deferred revenues  7,429   6,934 
         
Total current liabilities  25,275   24,949 
         
LONG-TERM LIABILITIES:        
Deferred revenues  538   644 
Convertible Debentures ($237 and $234 attributable to related parties, respectively)  8,541   9,248 
Long-term operating lease liabilities  8,574   9,866 
Deferred tax liability  425   655 
Accrued severance pay  924   838 
Other liabilities  497   706 
         
Total long-term liabilities  19,499   21,957 
         
COMMITMENTS AND CONTINGENCIES        
         
SHAREHOLDERS’ EQUITY:        
Ordinary shares nominal value ILS 0.15 par value -        
Authorized: 160,000,000 shares at September 30, 2021 (Unaudited) and 110,000,000 shares at December 31, 2020; Issued and Outstanding: 90,363,745 and 61,271,910 shares at September 30, 2021 (Unaudited) and December 31, 2020, respectively  3,745   2,392 
Additional paid-in capital  282,749   258,962 
Accumulated other comprehensive loss  (1,563)  (725)
Accumulated deficit  (264,164)  (248,592)
         
Total shareholders’ equity  20,767   12,037 
         
Total liabilities and shareholders’ equity $65,541  $58,943 

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

-3-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

($USD in thousands, except share and per share amounts)

(Unaudited)

 

  March 31,  December 31, 
  2019  2018 
  Unaudited    
ASSETS      
       
CURRENT ASSETS:      
Cash and cash equivalents $12,444  $17,571 
Trade receivables (net of allowances for doubtful accounts of $20 as of March 31, 2019 and December 31, 2018)  3,024   3,658 
Deferred commissions  909   887 
Prepaid expenses and other receivables  1,472   778 
         
Total current assets  17,849   22,894 
         
LONG-TERM ASSETS:        
Long-term deferred commissions  1,783   1,880 
Long-term restricted lease deposits  812   821 
Operating lease right-of-use assets  9,675   - 
Severance pay fund  541   503 
Property and equipment, net  4,692   4,608 
Intangible assets, net  8,554   8,802 
Goodwill  20,262   20,519 
         
Total long-term assets  46,319   37,133 
         
Total assets $64,168  $60,027 
  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
             
Revenues (1) $7,461  $9,114  $23,827  $27,944 
Cost of revenues  3,732   3,792   11,332   11,168 
                 
Gross profit  3,729   5,322   12,495   16,776 
                 
Operating expenses:                
                 
Research and development, net  4,100   4,769   12,460   12,264 
Sales and marketing  2,785   2,942   8,154   9,123 
General and administrative  2,336   2,302   6,801   6,992 
                 
Total operating expenses  9,221   10,013   27,415   28,379 
                 
Operating loss  (5,492)  (4,691)  (14,920)  (11,603)
                 
Other income (expense), net  5   1   (12)  9 
Financial expenses, net (1)  (320)  (235)  (821)  (757)
                 
Loss before taxes on income  (5,807)  (4,925)  (15,753)  (12,351)
Tax benefit  20   33   181   94 
                 
Net loss $(5,787) $(4,892) $(15,572) $(12,257)
                 
Basic and diluted net loss per share $(0.07) $(0.08) $(0.21) $(0.20)
                 
Weighted-average number of shares used in computing basic and diluted net loss per share  77,990   60,580   74,016   60,103 

 

(1)Transactions with related parties are included in the line item above (refer to Footnote 8, Related Parties, of the Notes to Consolidated Financial Statements for additional information).

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

-4-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

($USD in thousands, except share and per share amounts)

(Unaudited)

  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
             
Net loss $(5,787) $(4,892) $(15,572) $(12,257)
                 
Other comprehensive income (loss):                
                 
Foreign currency translation adjustments  (351)  591   (838)  590 
                 
Comprehensive loss $(6,138) $(4,301) $(16,410) $(11,667)

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

-5-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

($USD in thousands, except share amounts)

(Unaudited)

  Three months ended September 30, 2020 
  Number of
outstanding
ordinary
shares
  Share
capital
  Additional
paid-in
capital
  Accumulated
other
comprehensive
income
(loss) (*)
  Accumulated
deficit
  Total
shareholders’
equity
 
Balance as of June 30, 2020 (Unaudited)  60,197,223  $2,345  $257,045  $(2,011) $(238,694) $18,685 
Restricted stock units vested  225,000   10   (10)  -   -   - 
Payment of interest in shares  280,946   12   276   -   -   288 
Stock-based compensation related to employees, directors and consultants  -   -   724   -   -   724 
Issuance of shares upon early conversion of Convertible Debentures  216,334   9   142           151 
Other comprehensive loss  -   -   -   591   -   591 
Net loss  -   -   -   -   (4,892)  (4,892)
Balance as of September 30, 2020 (Unaudited)  60,919,503  $2,376  $258,177  $(1,420) $(243,586) $15,547 

  Nine months ended September 30, 2020 
  Number of
outstanding
ordinary
shares
  Share
capital
  Additional
paid-in
capital
  Accumulated
other
comprehensive
income
(loss) (*)
  Accumulated
deficit
  Total
shareholders’
equity
 
Balance as of December 31, 2019  59,372,173  $2,309  $255,741  $(2,010) $(231,329) $24,711 
Restricted stock units vested  856,132   38   (38)  -   -   - 
Payment of interest in shares  410,322   17   414   -   -   431 
Stock-based compensation related to employees, directors and consultants  -   -   1,876   -   -   1,876 
Issuance of shares upon early conversion of Convertible Debentures  280,876   12   184   -   -   196 
Other comprehensive loss  -   -   -   590   -   590 
Net loss  -   -   -   -   (12,257)  (12,257)
Balance as of September 30, 2020 (Unaudited)  60,919,503  $2,376  $258,177  $(1,420) $(243,586) $15,547 

-6-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

($USD in thousands, except share amounts)

(Unaudited)

  Three months ended September 30, 2021 
  Number of
outstanding
ordinary
shares
  Share
capital
  Additional
paid-in
capital
  Accumulated
other
comprehensive
income
(loss) (*)
  Accumulated
deficit
  Total
shareholders’
equity
 
Balance as of June 30, 2021 (Unaudited)  75,640,204  $3,056  $273,151  $(1,212) $(258,377) $16,618 
Stock and warrant issuance for financing, net of costs (***)  14,152,779   662   8,614   -   -   9,276 
Restricted stock units vested  236,250   11   (11)  -   -   - 
Payment of interest in shares  334,512   16   243   -   -   259 
Stock-based compensation related to employees, directors and consultants  -   -   752   -   -   752 
Other comprehensive loss  -   -   -   (351)  -   (351)
Net loss  -   -   -   -   (5,787)  (5,787)
Balance as of September 30, 2021 (Unaudited)  90,363,745  $3,745  $282,749  $(1,563) $(264,164) $20,767 

  Nine months ended September 30, 2021 
  Number of
outstanding
ordinary
shares
  Share
capital
  Additional
paid-in
capital
  Accumulated
other
comprehensive
income
(loss) (*)
  Accumulated
deficit
  Total
shareholders’
equity
 
Balance as of December 31, 2020  61,271,910  $2,392  $258,962  $(725) $(248,592) $12,037 
Stock issuance for financing, net of costs (**)  12,000,000   556   12,032   -   -   12,588 
Stock and warrant issuance for financing, net of costs (***)  14,152,779   662   8,614   -   -   9,276 
Restricted stock units vested  878,250   41   (41)  -   -   - 
Payment of interest in shares  859,334   39   621   -   -   660 
Stock-based compensation related to employees, directors and consultants  -   -   1,757   -   -   1,757 
Issuance of shares upon early conversion of Convertible Debentures  1,201,472   55   804   -   -   859 
Other comprehensive loss  -   -   -   (838)  -   (838)
Net loss  -   -   -   -   (15,572)  (15,572)
Balance as of September 30, 2021 (Unaudited)  90,363,745  $3,745  $282,749  $(1,563) $(264,164) $20,767 

(*)Relates to foreign currency translation adjustments.
(**)Net of issuance costs of $1,212.
(***)Net of issuance costs of $914

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

-7-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

($USD in thousands, except share and per share amounts)

(Unaudited)

  Nine months ended
September 30,
 
  2021  2020 
  Unaudited 
Cash flows from operating activities:      
       
Net Loss $(15,572) $(12,257)
Adjustments to reconcile net loss to net cash used in operating activities:        
Loss on disposal of property and equipment  17   12 
Depreciation  1,630   1,809 
Stock-based compensation  1,757   1,876 
Amortization of intangible assets  2,230   2,071 
Amortization of deferred commissions  1,010   1,181 
Amortization of operating lease right-of-use assets  1,269   1,508 
Interest on convertible notes  430   436 
Interest and amortization of debt issuance costs on Convertible Debentures  523   400 
Deferred taxes, net  (208)  (171)
         
Changes in assets and liabilities:        
         
Trade receivables  (2,900)  (126)
Prepaid expenses and other receivables  (711)  (456)
Deferred commissions  (773)  (900)
Change in long-term lease deposits and prepaids  (13)  (89)
Trade payables  85   (289)
Employees and payroll accruals, accrued expenses and other liabilities  127   (90)
Deferred revenues  527   1,034 
Accrued severance pay, net  (48)  (36)
Operating lease liabilities  (1,452)  (1,545)
Other long-term liabilities  (390)  184 
         
Net cash used in operating activities  (12,462)  (5,448)
         
Cash flows from investing activities:        
         
Proceeds from sale of property and equipment  6   6 
Capitalization of technology  (262)  (1,100)
Purchase of property and equipment  (466)  (1,543)
         
Net cash used in investing activities  (722)  (2,637)

The accompanying notes are an integral part of the interim consolidated financial statements.

 

- 2 -

-8-

 

 

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETSSTATEMENTS OF CASH FLOWS

($USD in thousands, except share and per share amounts)

(Unaudited)

 

  March 31,  December 31, 
  2019  2018 
  Unaudited    
LIABILITIES AND SHAREHOLDERS’ EQUITY      
       
CURRENT LIABILITIES:      
Trade payables $1,270  $1,668 
Employees and payroll accruals  3,375   3,959 
Accrued expenses and other liabilities  1,343   910 
Operating lease liabilities  1,277   - 
Earn-out consideration  -   2,926 
Deferred revenues  5,498   5,773 
         
Total current liabilities  12,763   15,236 
         
LONG-TERM LIABILITIES:        
Deferred revenues  3,242   503 
Convertible notes  10,000   10,000 
Long-term operating lease liabilities  8,724   - 
Deferred tax liability  1,045   1,130 
Accrued severance pay  677   598 
Other liabilities  347   700 
         
Total long-term liabilities  24,035   12,931 
         
COMMITMENTS AND CONTINGENCIES        
         
SHAREHOLDERS’ EQUITY:        
Ordinary shares nominal value ILS 0.15 par value -        
Authorized: 75,353,340 shares at March 31, 2019 (Unaudited) and December 31, 2018; Issued: 54,405,881 shares at March 31, 2019 (Unaudited) and December 31, 2018; Outstanding: 54,260,357 and 54,057,208 shares at March 31, 2019 (Unaudited) and December 31, 2018, respectively  2,097   2,097 
Additional paid-in capital  245,527   245,570 
Treasury shares at cost – 145,524 and 348,673 Ordinary shares at March 31, 2019 (Unaudited) and December 31, 2018, respectively  (416)  (998)
Accumulated other comprehensive loss  (2,038)  (1,666)
Accumulated deficit  (217,800)  (213,143)
         
Total shareholders’ equity  27,370   31,860 
         
Total liabilities and shareholders’ equity $64,168  $60,027 
  Nine months ended
September 30,
 
  2021  2020 
  Unaudited 
Cash flows from financing activities:      
       
Proceeds from Convertible Debentures, net of debt issuance costs  -   9,442 
Proceeds from stock and warrant issuance, net of costs  9,276   - 
Proceeds from stock issuance, net of costs  12,588   - 
         
Net cash provided by financing activities  21,864   9,442 
         
Effect of exchange rate changes on cash, cash equivalents and restricted cash  (36)  (14)
         
Increase in cash, cash equivalents and restricted cash  8,644   1,343 
Cash, cash equivalents and restricted cash at the beginning of the period  9,914   12,127 
         
Cash, cash equivalents and restricted cash at the end of the period $18,558  $13,470 
         
Supplemental cash flow disclosures:        
Cash paid during the year for:        
Interest $143  $144 
         
Supplemental disclosure of non-cash transactions:        
         
Purchase of property and equipment by credit $(25) $(214)
         
Operating lease right-of-use asset exchanged for lease obligations  -   3,772 
         
Issuance of shares on early conversion of Convertible Debentures  859   196 
         
Issuance of shares for payment of interest on convertible notes  143   144 
         
Issuance of shares for payment on Convertible Debentures  518   287 
         
Net change in accrued payroll expenses related to capitalization of technology  -   (26)
         
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:        
         
Cash and cash equivalents $17,932  $12,894 
Restricted cash included in long-term restricted lease deposits  626   576 
         
Total cash, cash equivalents and restricted cash $18,558  $13,470 

 

The accompanying notes are an integral part of the interim consolidated financial statements.

 

- 3 -

-9-

 

 

CYREN LTD.

CONDENSEDNOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF OPERATIONS

($USD in thousands, except share and per share amounts)

(Unaudited)

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
       
Revenues $9,655  $7,636 
Cost of revenues  4,000   3,382 
         
Gross profit  5,655   4,254 
         
Operating expenses:        
         
Research and development, net  4,177   3,355 
Sales and marketing  3,856   4,145 
General and administrative  2,432   2,038 
         
Total operating expenses  10,465   9,538 
         
Operating loss  (4,810)  (5,284)
   ��     
Other income (loss), net  248   (2)
Financial expenses, net  (53)  4 
         
Loss before taxes on income  (4,615)  (5,282)
Tax benefit  39   46 
         
Loss $(4,576) $(5,236)
         
Basic and diluted loss per share $(0.08) $(0.10)
         
Weighted average number of shares used in computing basic loss per share  54,177   53,381 
         
Weighted average numbers of shares used in computing diluted loss per share  54,177   53,381 

The accompanying notes are an integral part of the interim consolidated financial statements.

 

- 4 -

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

($USD in thousands, except share and per share amounts)

(Unaudited)

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
       
Loss $(4,576) $(5,236)
         
Other comprehensive income (loss):        
         
Foreign currency translation adjustments  (372)  374 
         
Comprehensive loss $(4,948) $(4,862)

The accompanying notes are an integral part of the interim consolidated financial statements.

- 5 -

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

($USD in thousands, except share and per share amounts)

(Unaudited)

  Number of outstanding ordinary shares  Share
capital
  Additional paid-in capital  Treasury shares  Accumulated other comprehensive income (loss) (*)  Accumulated deficit  Total shareholders’ equity 
Balance as of December 31, 2017  53,375,854   2,097   244,609   (3,312)  (1,195)  (195,098)  47,101 
Issuance of treasury shares upon exercise of options and vesting of restricted share units  11,686   -   (7)  43   -   (17)  19 
Stock-based compensation related to employees, directors and consultants  -   -   323   -   -   -   323 
Other comprehensive loss                  374       374 
Cumulative effect of accounting change  -   -   -   -   -   1,811   1,811 
Loss  -   -   -   -   -   (5,236)  (5,236)
Balance as of March 31, 2018 (Unaudited)  53,387,540  $2,097  $244,925  $(3,269) $(821) $(198,540) $44,392 

  Number of outstanding ordinary shares  Share
capital
  Additional paid-in capital  Treasury shares  Accumulated other comprehensive income (loss) (*)  Accumulated deficit  Total shareholders’ equity 
Balance as of December 31, 2018  54,057,208   2,097   245,570   (998)  (1,666)  (213,143)  31,860 
Issuance of treasury shares upon exercise of options and vesting of restricted share units  203,149   -   (312)  582   -   (81)  189 
Stock-based compensation related to employees, directors and consultants  -   -   269   -   -   -   269 
Other comprehensive loss                  (372)      (372)
Loss  -                   (4,576)  (4,576)
Balance as of March 31, 2019 (Unaudited)  54,260,357  $2,097  $245,527  $(416) $(2,038) $(217,800) $27,370 

NOTE 1:-(*)Relates to foreign currency translation adjustments.GENERAL

The accompanying notes are an integral part of the interim consolidated financial statements.

- 6 -

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

($USD in thousands, except share and per share amounts)

(Unaudited)

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
Cash flows from operating activities:      
       
Loss $(4,576) $(5,236)
Adjustments to reconcile loss to net cash used in operating activities:        
Loss on disposal of property and equipment  1   - 
Depreciation  461   455 
Stock-based compensation  269   323 
Amortization of intangible assets  966   1,009 
Amortization of deferred commissions  (332)  242 
Amortization of operating lease right-of-use assets  351   - 
Interest on convertible notes  140   - 
Other expenses (income) related to the earn-out consideration  (256)  27 
Deferred taxes, net  (69)  (47)
         
Changes in assets and liabilities:        
         
Trade receivables  678   587 
Prepaid expenses and other receivables  (738)  (659)
Deferred commissions  407   (359)
Change in long-term lease deposits  20   (3)
Trade payables  (405)  (39)
Employees and payroll accruals, accrued expenses and other liabilities  (274)  (252)
Deferred revenues  2,463   (509)
Accrued severance pay, net  41   8 
Operating lease liabilities  (365)  - 
Other long-term liabilities  (111)  61 
         
Net cash used in operating activities  (1,329)  (4,392)
         
Cash flows from investing activities:        
         
Capitalization of technology, net of grants received  (627)  (662)
Purchase of property and equipment  (544)  (822)
         
Net cash used in investing activities  (1,171)  (1,484)

The accompanying notes are an integral part of the interim consolidated financial statements.

- 7 -

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

($USD in thousands, except share and per share amounts)

(Unaudited)

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
Cash flows from financing activities:      
       
Payment of earn-out consideration  (2,680)  - 
Proceeds from options exercised  189   19 
         
Net cash provided by (used in) financing activities  (2,491)  19 
         
Effect of exchange rate changes on cash, cash equivalents and restricted cash  (126)  36 
         
(Decrease) in cash, cash equivalents and restricted cash  (5,117)  (5,821)
Cash, cash equivalents and restricted cash at the beginning of the period  18,156   24,228 
         
Cash, cash equivalents and restricted cash at the end of the period $13,039  $18,407 
         
Supplemental disclosure of non-cash transactions:        
         
Purchase of property and equipment by credit $(7) $(17)
         
Net change in accrued payroll expenses related to capitalization of technology $(143) $(230)
         
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:        
         
Cash and cash equivalents $12,444  $17,940 
Restricted cash included in long-term restricted lease deposits  595   467 
         
Total cash, cash equivalents and restricted cash $13,039  $18,407 

The accompanying notes are an integral part of the interim consolidated financial statements.

- 8 -

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 1:-GENERAL

Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated will be referred to in these consolidated financial statements as the “Company”.

 

The Company is engaged in developing and marketing informationcyber security solutions for protecting web,to identify and protect customers from threats in email, files, and mobile transactions.the web. The Company sells its cloud-based solutions worldwide, in both embeddeda Software-as-a-Service model, to enterprises as well to OEMs (Original Equipment Manufacturers) which include leading email providers, other cybersecurity vendors and Security-as-a-Service models, to Original Equipment Manufacturers (“OEMs”), servicemanaged services providers and enterprises.(MSPs). The Company operates in one reportable segment, which constitutes its reporting unit.

NOTE 2:-SIGNIFICANT ACCOUNTING POLICIES

 

a.Interim Financial Statements

 

The accompanying condensed consolidated balance sheet as of March 31, 2019,September 30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, and the consolidated statements of cash flows for the three months ended March 31, 2019 and 2018, as well as thecondensed statement of changes in shareholders’ equity for the three and nine months ended March 31, 2019,September 30, 2021 and 2020, as well as the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of March 31, 2019,September 30, 2021, as well as its results of operations and cash flows for the three and nine months ended March 31, 2019September 30, 2021 and 2018.2020. The results of operations for the three and nine months ended March 31, 2019September 30, 2021 are not necessarily indicative of the results to be expected for the year endingended December 31, 20192021 or for other interim periods or for future years.

 

b.

Over the past several years, the Company has devoted substantially most of its effort to research and development,made significant investment in product development, and increasing revenues through additional investments inas well as sales & marketing. The Company generated a loss of 4,576has incurred losses since inception and negative cash flow of 1,329 from operating activities in the three month period ended March 31, 2019, and has an accumulated deficit of 217,800 as of March 31, 2019. The Company is planning to finance its operations from its existing and future working capital resources andexpects to continue to evaluate additional sourcesincur losses for the foreseeable future. At September 30, 2021, the Company’s cash and cash equivalents position is not sufficient to fund the Company’s planned operations for at least one year beyond the date of capital and financing. However, therethe filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is no assurance that additional capital and/or financing will be available todependent upon the Company obtaining the necessary financing to meet its obligations and even if available, whether it will berepay its liabilities arising from normal business operations when they become due.

The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on terms acceptable tohand, reducing operating spend, potentially divesting non-core assets, amending certain existing debt securities and issuing equity and/or debt securities. On February 11, 2021, the Company orentered into securities purchase agreements with several institutional investors for the purchase and sale, in amounts required. Accordingly,a registered direct offering, of 12,000,000 of the Company’s Board approvedordinary shares at a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allowpurchase price of $1.15 per share for net proceeds of $12,588. On September 15, 2021, the Company entered into securities purchase agreements with several institutional investors to raise approximately $10,190 through the issuance of 14,152,779 of the Company’s ordinary shares and warrants to purchase up to 14,152,779 ordinary shares, at a purchase price of $0.72 per share and associated warrant, in a private placement priced "at-the-market" under Nasdaq Rules for net proceeds of $9,276.

The current cash balance and historical trend of cash used in operations along with the maturity of the convertible notes in December 2021, and lack of certainty regarding a future capital raise and our ability to renegotiate the terms of the convertible notes, raises substantial doubt about our ability to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainlyas a going concern for the following steps: reduction in consultants’ expenses, headcount, compensation paid to key management personnel and capital expenditures. The Company and the Board believe that its existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy its expected liquidity requirements for at leastnext twelve months from the filingdate of issuance of these financial statements. We anticipate that we will have sufficient funds to pay the principal of the convertible notes on their maturity date. While the Company has successful raised funds in the past, there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences on our financial condition and results of operations.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

The condensed consolidated financial statements for the three and nine months ended September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

 

-10-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 2:-c.SIGNIFICANT ACCOUNTING POLICIES (Cont.)

c.Significant accounting policies

 

The accompanying unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2019.30, 2021.

 

Other than the change described below, there have been no changes to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended December 31, 20182020 that have had a material impact on the unaudited interim consolidated financial statements and related notes.

 

- 9 -

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 2:-d.SIGNIFICANT ACCOUNTING POLICIES (Cont.)Use of estimates:

 

d.Use of estimates:

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair value and useful lives of intangible assets, fair value of earn-out liabilities, valuation allowance on deferred tax assets, income tax uncertainties, fair values of stock-based awards, other contingent liabilities and estimates used in applying the revenue recognition policy. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

 

e.Recently issued and adopted pronouncements:Going Concern

 

In June 2018,The accompanying condensed consolidated financial statements have been prepared assuming the FASB issued ASU No. 2018-07, ”Compensation – Stock Compensation (Topic 718): ImprovementsCompany will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

U.S. GAAP requires an evaluation of whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to Nonemployee Share-Based Payment Accounting.” These amendments expandcontinue as a going concern within one year after the scopedate the financial statements are issued. Initially, this evaluation does not consider the potential mitigating effect of Topic 718, Compensation - Stock Compensation (which currently only includes stock-based payments to employees) to include stock-based payments issued to nonemployees for goods or services. Consequently,management’s plans that have not been fully implemented. When substantial doubt exists, management evaluates the accounting for stock-based payments to nonemployees and employeesmitigating effect of its plans if it is probable that (1) the plans will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity - Equity-Based Paymentseffectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to Non-Employees. Adoptioncontinue as a going concern within one year after the date the financial statements are issued or prior to the conditions or events that create the going concern risk.

The condensed consolidated financial statements as of this standard had an immaterial impactSeptember 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s consolidated financial statements.ability to continue as a going concern.

 

- 10 -

-11-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

 

NOTE 2:-SIGNIFICANT ACCOUNTING POLICIES (Cont.)

f.Basic and diluted net loss per share:

 

Basic net loss per share has been computed using the weighted-average number of ordinary shares outstanding during the period. Diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus the weighted average number of dilutive potential ordinary shares considered outstanding during the period.

Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. In periods where the Company reports a net loss, the effect of anti-dilutive stock options, restricted stock units, convertible notes, Convertible Debentures, and warrants are excluded and diluted net loss per share is equal to basic net loss per share. For the three months period ended September 30, 2021 and September 30, 2020, 26,877,551 and 24,093,385 ordinary shares were excluded from the calculation of diluted net EPS due to their anti-dilutive effect, respectively. For the nine months period ended September 30, 2021 and September 30, 2020, 42,098,143 and 74,627,734 ordinary shares were excluded from the calculation of diluted net EPS due to their anti-dilutive effect, respectively.

g.Recently issued and adopted pronouncements:

In February 2016,December 2019, the FASB issued ASU 2016-02, “Leases”, onNo. 2019-12, “Simplifying the recognition, measurement, presentation and disclosure of leasesAccounting for both parties to a contract (i.e., lessees and lessors). The new standard supersedesIncome Taxes” under ASC 740, which simplifies the lease requirements in Accounting Standards Codification (ASC) Topic 840, “Leases” and requires lessees, to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchaseaccounting for income taxes by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a manner similarremoving certain exceptions to the accounting undergeneral principles in Topic 740 and amends existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements to Topic 842, which provides an alternative transition method at the transition date, allowing entities to recognize a cumulative effect adjustment to the opening balance of retained earnings upon adoption. Theimprove consistent application. This guidance is effective for the interim and annual periods beginning on or after December 15, 2018, and early adoption is permitted. The Company adopted ASU 2016-02 as of January 1, 2019.

f.New accounting pronouncements not yet adopted:

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. ASU 2017-04 is effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019,2020, including interim periods within that fiscal year. The Company adopted this new guidance in the first quarter of fiscal 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements. 

h.New accounting pronouncements not yet adopted:

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and earlyOther Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.statements.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update to the standard is effective for interim an annual periods beginning after December 15, 2019, with early adoption permitted. Entities can choose to adopt the ASU 2018-15 prospectively or retrospectively. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and footnote disclosures.

 

- 11 -

-12-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

 

NOTE 3:-NOTE 2:-SIGNIFICANT ACCOUNTING POLICIES (Cont.)LEASES

 

g.Leases:

The Company adopted ASC 842, Leases, the new standard as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a full retrospective approach. The Company has elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard which does not require it to reassess the prior conclusions about lease identification, lease classification, and initial direct costs.

 

In addition, the Company has elected the short-term lease exception for leases with a term of 12 months or less. As part of this election, it will not recognize right-of-use assets and lease liabilities on the balance sheet for leases with terms less than 12 months. The Company also elected the practical expedient to not separate lease and non-lease components for all our leases. This will result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability being greater than if the policy election was not applied.

 

Some leases include one or more options to extend the lease. The exercise of options to extend the lease is typically at the Company’s sole discretion; therefore, the majority of renewals to extend the lease terms are included in our right of use assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. Lease modifications result in the remeasurement of the lease liability.

 

The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of adoption in determining the present value of the lease payments.

 

Some of the real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease adoption. Additional payments based on the change in an index or rate are recorded as a period expense when incurred. 

 

- 12 -

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 2:-SIGNIFICANT ACCOUNTING POLICIES (Cont.)

g.Leases:

The Company has various operating leases for office space and vehicles that expire through 2030. Below is a summary of our operating right-of-use assets and operating lease liabilities as of March 31, 2019:September 30, 2021:

 

Operating lease right-of-use assets $9,675 
     
Operating lease liabilities, current $1,277 
Operating lease liabilities long-term  8,724 
     
Total operating lease liabilities $10,001 
Operating lease right-of-use assets $9,431 
     
Operating lease liabilities, current $1,638 
Operating lease liabilities long-term  8,574 
     
Total operating lease liabilities $10,212 

 

The short term lease liabilities is included within accrued expenses

-13-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and other short term liabilities in the consolidated balance sheet.per share amounts)

(Unaudited)

 

NOTE 3:-LEASES (Cont.)

Minimum lease payments for our right of use assets over the remaining lease periods as of March 31, 2019,September 30, 2021, are as follows:

 

Year ended December 31,   
2019 $1,403 
2020  1,854 
2021  1,752 
2022  1,207 
2023  1,055 
Thereafter  4,298 
     
Total undiscounted lease payments $11,569 
     
Less: Interest  1,568 
     
Present value of lease liabilities  10,001 

Year ended December 31,   
2021 $595 
2022  1,827 
2023  1,632 
2024  1,629 
2025  1,626 
Thereafter  4,439 
     
Total undiscounted lease payments $11,748 
     
Less: Interest  1,536 
     
Present value of lease liabilities $10,212 

 

Premises rent expense was $467$679 and $441$714 for the three months ended March 31, 2019September 30, 2021 and 2018,2020, respectively, and $2,100 for the nine months ended September 30, 2021 and 2020.

As of September 30, 2021, the Company subleases two real estate properties. Sublease receipts were $167 and $171 for the three months ended September 30, 2021 and 2020, respectively, and $496 and $361 for the nine months ended September 30, 2021 and 2020, respectively.

 

As of March 31, 2019,The Company has elected the Company had an additional operatingpractical expedient to not separate lease that had not yet commenced in the amount of $3,675. This operating lease will commence in the first quarter of 2020 with a lease term through 2029.components from non-lease components. 

 

The weighted averageweighted-average remaining lease terms and discount rates for all of operating leases were as follows as of March 31, 2019:September 30, 2021:

 

Remaining lease term and discount rate:   
    
Weighted averageWeighted-average remaining lease term (years)  3.56.7 
     
Weighted averageWeighted-average discount rate  4.164.35%

 

- 13 -

-14-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 4:-NOTE 3:-COMMITMENTS AND CONTINGENCIES

 

a.Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel.

 

In connection with specific research and development, the Company received $3,699 of participation payments from the IIA through March 31, 2019.2018 and none since 2018. In return for the IIA’s participation in this program, the Company is committed to paypaying royalties at a rate of 3.5%3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate. The Company’s total commitment for royalties payable with respect to future sales, based on IIA participations received, net of royalties paid or accrued, totaled $2,834$2,610 and $2,734$2,713 as of March 31, 2019September 30, 2021 and December 31, 20182020, respectively. For the three months ended, September 30, 2021 and 2020, $31 and $64, respectively, were recorded as cost of revenues with respect to royalties due to the IIA. For the nine months ended, September 30, 2021 and 2020, $90 and $173, respectively, were recorded as cost of revenues with respect to royalties due to the IIA.

 

b.Litigations:

 i.b.

Between 2014 and 2015 the Company entered into arbitral proceedings with the former shareholders of eleven regarding an escrow account and the earn-out consideration related to the purchase agreement of former eleven. With respect to these claims, on March 9, 2017, the arbitrational panel provided their ruling in which it accepted the claims submitted by the former eleven shareholders with respect to the escrow amount and the 2013 earn-out liability. The arbitrational panel also ruled that Cyren pay legal expenses and interest on the claimed amounts, which were reflected in the year ending December 31, 2016 on the Company’s balance sheet and in the consolidated statements of operations under adjustment to earn-out consideration.

The escrow account has been released to the former shareholders. The arbitrational award related to the 2013 earn-out consideration was declared enforceable by the applicable courts in Germany. Accordingly, on May 30, 2018, the Company paid the portion of the earn-out consideration in the amount of $604 that was declared enforceable by the German district court. The Company did not pay the remainder of the earn-out consideration, including accrued legal and interest, which appear on the Company’s consolidated balance sheets as of December 31, 2018, and has filed an appeal to the German Federal Supreme Court challenging the enforceability of the remaining amounts.

In February 2019, the parties have signed a settlement agreement to resolve all pending claims, and on February 28, 2019 the Company paid $2,680 to settle the earn-out consideration in full. The total amount paid to resolve all claims was $256 less than the accrued liability, which generated “other income” as reflected in the consolidated statement of operations for the period ending March 31, 2019.

Litigation:

 

- 14 -

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USDOn June 28, 2017 a vendor filed a Statement of Claim in thousands, except sharethe Tel Aviv District Court (the “SOC”). According to the vendor’s SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claimed that the Company had continued to make use of the vendor’s database post termination thus breaching the agreement, infringing on the vendor’s rights and per share amounts)

(Unaudited)commercial secrets, and being unjustly enriched.

 

NOTE 3:-COMMITMENTS AND CONTINGENCIES (Cont.)

ii.On June 28, 2017 a vendor filed a Statement of Claim in the Tel Aviv District Court (the “SOC”). According to the vendor’s SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claims that the Company continues to make use of the vendor’s database post termination, thus breaching the agreement, infringing on the vendor’s rights and commercial secrets, and being unjustly enriched.

The vendor is claiming license feesclaimed damages of approximately $3,150 and an injunctioninjunctive relief ordering the Company and/or its customers to delete any remaining data and to cease from utilizing such data.

 

The Company deniesdenied all claims and has filed a Statement of Defense on November 15, 2017. Pretrial was scheduled for May 15, 2018. In accordance with the court’s recommendation from November 28, 2017, the parties agreed to examine a non-binding mediation process and have appointed a mediator. The parties agreed to conduct a third partythird-party audit of the Company’s databases in the scope of the mediation and the audit is currently being conducted. At this early stage, the Company is unable to make any estimations as to the outcome of this litigation.mediation.

 

In September 2018 and January 2019, the same vendor filed a lawsuit against two of the Company’s customers in the United States. The vendor allegesalleged that the clients misappropriated the vendor’s trade secrets and is seekingsought injunctive relief and monetary damages in an amount to be determined. Both customers have contended that the allegations relaterelated to the services they receive from the Company, and the Company has agreed to indemnify both clients against these claims. On September 30, 2019, the court dismissed one of the lawsuits in its entirety for lack of personal jurisdiction and, in the second lawsuit, dismissed part of the claims with prejudice but granted the vendor the right to amend its other claims. On October 31, 2019, the vendor filed an amended complaint. In December 2019, the Company reached a settlement with the vendor and the Company agreed to pay $750; $375 in December 2019 and the remaining portion in January 2020. As such,of March 31, 2021, the Company has taken over the representationpaid all amounts due under this settlement.

-15-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in these lawsuits. At this early stage, the Company is unable to make any estimations as to the outcome of these litigations.thousands, except share and per share amounts)

(Unaudited)

 

NOTE 5:-NOTE 4:-ShareHOLDERS’ EQUITY

 

a.General:

Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends if declared. On July 8, 2021, the shareholders of the Company approved an increase in the number of authorized ordinary shares from 110,000,000 ordinary shares of nominal value NIS 0.15 per share to 160,000,000 ordinary shares of nominal value NIS 0.15 per share.

 

b.Issuance of new convertible notes:

 

On December 5, 2018 the Company issued $10,000 aggregate principal amount of convertible notes in a private offering. The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and are expected to mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes havewere issued with a conversion price of $3.90 per share. The conversion price may beshare which was subject to adjustment using a weighted averageweighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019, Cyren announced the closing of a rights offering that raised gross proceeds of $8,019. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. On February 16, 2021, Cyren announced securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. On September 17, 2021, we issued to several institutional investors in a private placement 14,152,799 of our ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02. In addition, the notes would be subject to immediate conversion upon any change in control in the Company.Company (or subject to repayment if the price in the change in control transaction is less than the conversion price).

 

- 15 -The Company incurred interest expense for the three and nine months ended September 30, 2021 of $145 and $430, respectively. The Company incurred interest expense for the three and nine months ended September 30, 2020 of $153 and $436, respectively. In June 2021, the Company paid semi-annual interest payments totaling, $287, of which $143 was paid in cash and the remaining portion through the issuance of 233,400 shares. The Company has accrued interest of $176 as of September 30, 2021.

As of September 30, 2021, the principal balance of the convertible notes is $10,000.

As the convertible notes mature in December 2021, the Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. If the restructuring discussions are not successful, the Company intends to use its available cash resources to repay the principal upon maturity per the terms of the convertible notes. 

-16-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:-NOTE 4:-SHAREHOLDERS’ EQUITY (Cont.)

c.Issuance of Convertible Debentures :

 

In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10,250 aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9,400 (net of $800 in issuance expenses).

The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $0.75 per share and are convertible into 1,333 ordinary shares per $1,000 principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures.

In March 2021, the Company paid semi-annual interest payments totaling, $259, which was paid through the issuance of 291,422 shares.

In September 2021, the Company paid semi-annual interest payments totaling, $259, which was paid through the issuance of 334,512 shares.

For the quarter ended March 31, 2021, two debenture holders converted $909 of principal plus interest of their debentures, which was a portion of their holding. The principal and interest were paid through the issuance of 1,201,472 shares. There were no conversions for the quarters ended June 30, 2021 or September 30, 2021.

On June 11, 2020, one of the debenture holders converted $48 of principal plus interest of their debentures, which was a portion of their holding. The principal and interest was paid through the issuance of 64,542 shares.

The Company incurred interest expense for the three and nine months ended September 30, 2021 of $180 and $523, of which $44 and $134 are related to the amortization of debt issuance costs, respectively. The Company incurred interest expense for the three and nine months ended September 30, 2020 of $188 and $400, of which $49 and $98 are related to the amortization of debt issuance costs, respectively.

The Company has accrued interest of $20 as of September 30, 2021.

The principal balance of the Convertible Debentures as of September 30, 2021 was $9,000. As of September 30, 2021, the total estimated fair value of the Convertible Debentures was approximately $5,600. The fair value was determined based on the closing trading price of $0.62 per share multiplied by the Convertible Debentures principal balance as of the last day of trading for the period The fair value of the Convertible Debentures is considered a Level 2 within the fair value hierarchy and was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted price of the Convertible Debentures in an over-the-counter market.

 c.d.Equity Incentive Plan:

 

In 1996, the Company adopted the 1996 CSI Share Option Plan for granting options to its U.S. employees and consultants to purchase ordinary shares of the Company, which was replaced in 2006 by the 2006 U.S. Share Option Plan. Until 1999, the Company issued options to purchase ordinary shares to its Israeli employees pursuant to individual agreements. In 1999, the Company approved the 1999 Section 3(i) stock option plan for its Israeli employees and consultants, (which was amended in 2003 and renamed the “Amended and Restated Israeli Share Option Plan”). On December 22, 2016, the Company’s shareholders approved a new stock optionequity plan - the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its respective Israeli appendix, has replaced all existingthen-existing employee and consultants stock option plans which have terminated.plans.

 

-17-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:-SHAREHOLDERS’ EQUITY (Cont.)

The Equity Incentive Plan allows for the issuance of Restricted ShareStock Units (“RSUs”), as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon the termination of the optionee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are canceledcancelled or not exercised within the option term become available for future grant.

 

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000.

As of March 31, 2019,September 30, 2021, an aggregate of 1,260,4986,481,815 ordinary shares of the Company are still available for future grant under the Equity Incentive Plan.

 

d.e.Non-Employee Directors stock option plan:

 

In 1999, the Company adopted the 1999 Directors ShareStock Option Plan, and in 2008 shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company’s shareholders approved a new stock optionequity plan - the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its respective Israeli appendix, has replaced all existing Directors stock option plans which have terminated.plans.

 

The Non-Employee Director Plan allows for the issuance of Restricted ShareStock Units (“RSUs”), as well as options. Each option and RSU granted under the Non-Employee Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon the termination of the relationship with the Company.

 

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares.

As of March 31, 2019,September 30, 2021, an aggregate of 170,214698,050 ordinary shares of the Company are still available for future grant to non-employee directors.

 

- 16 -

-18-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:-NOTE 4:-SHAREHOLDERS’ EQUITY (Cont.)

 

e.f.A summary of the Company’s employees and directors’ stock option activity under the plans is as follows:

 

  Number of options  Weighted average exercise price  Weighted average remaining contractual term (years)  Aggregate intrinsic value 
             
Outstanding at December 31, 2018  6,474,982  $2.28   3.39  $4,475 
                 
Granted  217,500   2.52         
Exercised  (105,899)  1.78         
Expired and forfeited  (169,006)  2.69         
                 
Outstanding at March 31, 2019  6,417,577  $2.29   3.24  $1,071 
                 
Options vested and expected to vest at March 31, 2019  6,283,474  $2.33   3.19  $1,071 
                 
Exercisable options at March 31, 2019  5,015,181  $2.26   2.68  $1,071 
                 
Weighted average fair value of options granted during the quarter     $1.03         
  Number of
options
  Weighted-
average
exercise
price
  Weighted-
average
remaining
contractual
term
(years)
  Aggregate
intrinsic
value
 
             
Outstanding at December 31, 2020  6,205,860  $2.09   3.18  $       - 
                 
Granted  230,000   0.75         
Exercised  -   -         
Expired and forfeited  (2,785,270)  2.16         
                 
Outstanding at September 30, 2021  3,650,590  $1.95   2.95  $2 
                 
Options vested and expected to vest at September 30, 2021  3,558,211  $1.96   2.92  $2 
                 
Exercisable options at September 30, 2021  2,536,407  $2.03   2.46  $- 
                 
Weighted-average fair value of options granted during the quarter     $0.39         

 

The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period.

The total intrinsic value of options exercised during the quarters ended September 30, 2021 and 2020 was $0, and $0, respectively.

The weighted-average grant date fair value of options granted to employees and directors during the quarters ended September 30, 2021 and 2020, was $0.39 and $0.66, respectively.

As of March 31, 2019,September 30, 2021, the Company had $1,715$750 of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted averageweighted-average period of 3.131.73 years.

 

f.g.The employee and director options outstanding as of March 31, 2019,September 30, 2021, have been separated into ranges of exercise prices, as follows:

 

Outstanding Exercisable 
Exercise    Weighted average remaining contractual  Weighted average exercise     Weighted average exercise 
price per Options  life in  price per  Options  price per 
share outstanding  years  share  exercisable  share 
                
$1.44 - $1.93  1,410,802   3.09  $1.56   1,410,802  $1.56 
$2.00 - $2.13  1,503,869   3.76  $2.03   1,503,869  $2.03 
$2.29 - $2.79  1,656,906   3.73  $2.48   762,510  $2.58 
$3.00 - $3.14  1,523,000   2.74  $2.99   1,027,000  $3.02 
$3.16 - $3.32  323,000   1.29  $3.32   311,000  $3.32 
                     
   6,417,577   3.24  $2.34   5,015,181  $2.26 
Outstanding  Exercisable 
     Weighted-
average
remaining
contractual
  Weighted-
average
exercise
     Weighted-
average
exercise
 
  Options  life in  price per  Options  price per 
Exercise price per share outstanding  years  share  exercisable  share 
                
$0.54 - $1.64  989,162   3.23  $1.37   546,152  $1.52 
$1.70 - $2.00  705,550   2.05  $1.89   621,346  $1.91 
$2.05 - $2.14  1,133,640   3.51  $2.09   679,896  $2.09 
$2.30 - $2.75  644,912   2.53  $2.39   552,705  $2.38 
$2.90 - $3.20  177,326   2.90  $2.90   136,308  $2.96 
                     
   3,650,590   2.95  $1.95   2,536,407  $2.03 

- 17 --19-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:-NOTE 4:-SHAREHOLDERS’ EQUITY (Cont.)

h.Options to non-employees and non-directors:

gOptions to non-employees:
Issuance date Options
outstanding
  Exercise
price per
share
  Options
exercisable
  Exercisable
through
            
February 10, 2016  40,000  $1.44   40,000  Feb-22
January 24, 2017  25,000  $2.00   25,000  Jan-23
               
   65,000       65,000   

 

Issuance date Options outstanding  Exercise price per share  Options exercisable  Exercisable through
            
August 1, 2013  150,000  $3.08   150,000  Aug-19
May 14, 2014  3,000  $3.32   3,000  May-20
February 18, 2015  3,000  $3.00   3,000  Feb-21
February 10, 2016  40,000  $1.44   40,000  Feb-22
January 24, 2017  25,000  $2.00   25,000  Jan-23
               
   221,000       221,000   

The options vest and become exercisable at a rate of 1/16 of the options every three months.

 

As of September 30, 2021, the Company did not have any unrecognized compensation expense related to non-employee and non-director non-vested stock options.

h.i.A summary of the Company’s RSUs activity for employees, directors, and non-employees under the plans is as follows:

 

Number of RSUs
Awarded and unvested at December 31, 2018479,000
Granted566,927
Vested(97,250)
Forfeited(15,000)
Awarded and unvested at March 31, 2019933,677
  Number
of RSUs
  Weighted- average
grant date
fair value
 
       
Awarded and unvested at December 31, 2020  2,183,500  $1.50 
         
Granted  5,233,400   0.83 
Vested  (878,250)  1.49 
Forfeited  (152,500)  1.29 
         
Awarded and unvested at September 30, 2021  6,386,150  $0.96 

As of March 31, 2019,September 30, 2021, the Company had approximately $2,284$5,225 of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted averageweighted-average period of 3.552.62 years.

 

- 18 -

-20-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 5:-NOTE 4:-SHAREHOLDERS’ EQUITY (Cont.)

 

i.j.The total stock-based compensation expense related to all of the Company’s equity-based awards, recognized for the three month periodsand nine months ended March 31, 2019September 30, 2021 and 20182020 was as follows:

 

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
       
Cost of revenues $29  $31 
Research and development  67   91 
Sales and marketing  49   101 
General and administrative  124   100 
         
  $269  $323 
  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
             
Cost of revenues $83  $21  $187  $85 
Research and development  55   70   150   229 
Sales and marketing  100   65   228   204 
General and administrative  514   568   1,192   1,358 
                 
  $752  $724  $1,757  $1,876 

 

NOTE 6:-NOTE 5:-SEGMENT AND GEOGRAPHIC INFORMATION

 

Summary information about geographic areas:

 

ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makerdecision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance, and technical support (see note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas:

 

a.The following sets forth total revenue by solutions offered by geographic area based on the billing address of the customer:

 

  Three Months Ended 
March 31,
 
  2019  2018 
       
United States $4,566  $2,750 
Europe  3,132   3,217 
Asia Pacific  610   775 
Israel  1,264   605 
Other  83   289 
         
  $9,655  $7,636 

  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
             
United States $3,200  $4,201  $10,413  $13,075 
Germany  1,991   2,109   6,120   6,269 
Europe  851   966   2,788   2,993 
Asia Pacific  443   667   1,606   1,900 
Israel  849   1,001   2,535   3,350 
Other  127   170   365   357 
                 
  $7,461  $9,114  $23,827  $27,944 

 

- 19 -

-21-

 

 

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 6:-NOTE 5:-SEGMENT AND GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Cont.)

b.Major customers:

 

b.Major customers:

During the quarter ended March 31, 2019, 20%September 30, 2021 and 2020, 17% and 22%, respectively, of the Company’s revenues were derived from customer A. Duringa single customer. For the quarter ended March 31, 2018,September 30, 2021, no other customer accounted for more than 10% of total revenue.

 

c.Remaining performance obligations:

As of September 30, 2021, approximately $26,625 of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 26% of these remaining performance obligations during the remainder of 2021, approximately 51% in 2022, with the remainder recognized thereafter.

d.Revenue generated by Customer Type:

  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
             
OEM/Embedded Security (*) $5,876  $7,354  $18,940  $22,771 
Enterprise/SMB (**)  1,585   1,760   4,887   5,173 
  $7,461  $9,114  $23,827  $27,944 

(*)This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users.
(**) In this market, Cyren provides enterprise customers email security products, threat intelligence, and cloud-based sandbox threat analysis to protect their employees, data and IP.

e.The following sets forth the Company’s property and equipmentlong-lived tangible assets, net by geographic area:

 

  March 31,  December 31 
  2019  2018 
  Unaudited    
       
Israel $1,332  $1,217 
United States  1,690   1,623 
Germany  1,364   1,453 
Other  306   315 
         
  $4,692  $4,608 
  September 30,  December 31 
  2021  2020 
  Unaudited    
       
Israel $5,852  $6,490 
United States  971   1,964 
Germany  4,374   5,247 
Other  962   1,147 
         
  $12,159  $14,848 

 

-22-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

($USD in thousands, except share and per share amounts)

(Unaudited)

NOTE 7:-NOTE 6:-RELATED PARTIESFINANCIAL EXPENSE, NET

 

  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
Expenses:            
Interest expense, net of interest capitalized $(333) $(410) $(964) $(902)
Foreign currency exchange differences, net  29   190   194   196 
Other  (16)  (15)  (51)  (51)
                 
  $(320) $(235) $(821) $(757)

NOTE 8:-RELATED PARTIES

 a.Balances with related parties:

  March 31,  December 31, 
  2019  2018 
  Unaudited    
       
Prepaid expenses (*) $-  $6 
  September 30,  December 31, 
  2021  2020 
  Unaudited    
       
Interest expense accrual – Convertible Notes (*) $176  $32 
Interest expense accrual – Convertible Debentures (**)  1   4 
Short term Convertible Notes (***)  10,000   10,000 
Long term Convertible Debentures (****)  237   234 

(*)(*)Related to a software license agreement with athe semi-annual interest payable due in June and December related party.to the convertible notes entered into December 5, 2018. See note 6b.5b. for further details.
(**)Related to the semi-annual interest payable due in September and March related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.
(***)Related to the convertible notes entered into December 5, 2018. See note 5b. for further details.
(****) Related to the Convertible Debentures entered into March 19, 2020 See note 5c. for further details.

b.Transactions with related parties:

 

  

Three months ended

March 31,

 
  2019  2018 
  Unaudited 
       
Software licensing expenses (**) $6  $6 
  Three months ended
September 30,
  Nine months ended
September 30,
 
  2021  2020  2021  2020 
  Unaudited  Unaudited 
Revenue (*) $17  $-  $17  $- 
                 
Interest expense on Convertible Notes (**) $145  $153  $430  $436 
Interest expense on Convertible Debentures (***) $5  $5  $15  $10 

 

(*)Related to a new OEM customer agreement signed in Q3 2021 where Cyren and this customer share the same investor.
(**)Expenses arising from a software licensing agreement which was executedRelated to the semi-annual interest payable due in June and December related to the convertible notes entered into December 5, 2018. See note 5b. for further details.
(***) Related to the semi-annual interest payable due in September and March 2017. Atrelated to the time of execution, the vendor was not a related party. On December 24, 2017, upon completion of the tender offer by WP, the vendor became a related party. The expenses were recorded under research and development expenses net, on the consolidated statements of operations.  The agreement endedConvertible Debentures entered into March 31, 2019 and has not been renewed.19, 2020. See note 5c. for further details.

- - - - - - - - - - - - -

-23-

 

 

- 20 -

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto. The following discussion and analysis includes forward-looking statements that involve certain risks and uncertainties, including, but not limited to, those described in Item 1A. Risk Factors in our most recent Annual Report on Form 10-K (the “2018“2020 Annual Report”). and Item 1A. Risk Factors in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. Our actual results may differ materially from those discussed below. See “Special Note Regarding Forward-Looking Statements” below.

Overview

 

Purpose built for the cloud, Cyren iswas an early pioneer and leading innovator of SaaS securitycloud delivered Software-as-a-Service (SaaS) cybersecurity solutions that protect businesses, and their employees and customers against threats from threats onemail, files, and the web, in email and on mobile devices. Our mission is to protect people and organizations from cyber threats when they use the internet.web.

 

Cyren’s cloud-firstWe believe our cloud-based approach to security sets us apart from other vendors in the market. Cyren is an internet security company that is delivering security results that are disrupting legacy vendors and appliance-based solutions. Our security solutions are architected around the fundamental belief that internetcyber security is a race against time – and the cloud best enables the speed, sophistication, and advanced automation needed to detect and block threats as they emerge on the internet. As more and more businesses move their data and applications to the cloud, they need a security provider that is able to keep pace.

 

Cyren’sSecurity threats are more prevalent and stealthier than ever. As cybercrime has become more sophisticated, every malware, phishing, and ransomware variant is unique, making it more difficult to detect attacks. While organizations have traditionally protected their users with gateway security cloud delivers faster detectionappliances at their network perimeter, more frequent and protection,evasive attacks combined with SaaS security solutionsa more distributed workforce are reducing the effectiveness of this approach. Traditional appliances lack the real-time threat intelligence and processing power to detect emerging threats, and the growth of mobile devices and an increasingly distributed workforce means that inspect webmore and email traffic before it reachesmore business is conducted outside of the traditional network perimeter. As a user’s browserresult, when new attacks appear in a matter of seconds, legacy cybersecurity products can leave companies vulnerable for hours, days, or inbox – often identifying and blocking threats in just seconds. Our SaaS solutions are easy to deploy and manage, delivering critical security and faster innovation, for a low total cost of ownership.even weeks.

 

Cyren’s cloud security products and services are soldfall into two markets:three categories:

 

·Cyren CloudThreat Detection Services – these services detect a variety of threats in email, files, and from the web, and are embedded into products from the world’s leading email providers, cyber security vendors and managed service providers. Cyren Threat Detection Services include our Email Security (CCS)Detection Engine, Malware Detection Engine, Web Security Engine, and Threat Analysis Service.

Cyren Threat Intelligence Data – Cyren’s Threat Intelligence Products provide valuable threat intelligence data that can be used by enterprise or OEM customers to support threat detection, threat hunting, and incident response. Cyren’s Threat Intelligence offerings include IP Reputation Intelligence, Phishing Intelligence, Malware Intelligence, and Zombie Intelligence.

Cyren Enterprise Email Security Productsthis SaaS security platform isthese include cloud-based solutions designed for enterprise customers and isare sold either directly or through channel partners. Cyren Cloud Security (CCS) services currently includeEnterprise Email Security (CES), Web Security (CWS), DNS Security, and Cloud Sandboxing. Each of these service offerings may be purchased separately, or as part of a bundled suite. All products are sold on a per-user SaaS subscription model, providing customers with a quick-to-deploy, easy-to-manage solution and a low total cost of ownership. We market and sell our solutions worldwide both directly through our sales teams and indirectly through our Partner Program where our sales organization actively assists our network of distributors and resellers.

·include Cyren Threat Intelligence Services (TIS) –this platform offers cloud-based cyber threat detection APIs, and SDKs to many of the world’s leading technology and security vendors. Cyren Threat Intelligence Services include Email Security, Weba cloud-based secure email gateway, and Cyren Inbox Security, Endpoint Security, and Advanced Threat Protection. These solutions are sold directly to Original Equipment Manufacturers (“OEMs”), embedded security vendors, and service providers that integrate Cyren Threat Intelligence Services and cloud detection services into their infrastructure or security products to protect their customers and users.an anti-phishing product for Microsoft 365.

 

Key Opportunities and Challenges

 

Threat Landscape

 

Over theThe last several years have possibly experienced the greatest magnitudeamount of significantdramatic global incidents directly related to malware and cyber threats have occurred since the advent of the internet. From election hacks to global ransomware attacks, and cyber breaches, malware threats are at an all-time high. Today,Phishing attacks have become increasingly common, and no itemcompany, large or user connected to the internet issmall seems immune to attack. While many businesses are still exploring effective security measures, cybercriminals are “all in”, creating dangerous new toolsthese threats. Hackers have become more successful at monetizing these attacks, and as long as these activities prove lucrative, we expect these incidents to target companies, governments, and private citizens. We need to be mindful that the world has changed; hyper-evasive malware and threat distribution via HTTPS are growing rapidly, mobile devices are increasingly targets, and Internet of Things (IoT) devices, from refrigerators to televisions, are an inviting new vector for criminal attacks.continue. 

- 21 -

 

-24-

Cloud and Mobility

 

Businesses are going through a massive change in their IT strategies as they look to drive more business value, agility, and better customer experiences, while cloud and mobility are becoming increasingly important, as evidenced by the following trends:

 

·Business internet traffic continues to increase every year;

·Data and applications are increasingly moving to the cloud;

·More and more users are working remotely;remotely, particularly since the COVID-19 pandemic;

·Buyers continue to move away from traditional on-premise solutions;

·Mature and legacy on premiseon-premise deployments are reaching the end of life and are increasingly being replaced by cloud and SaaS alternatives;

·IT security staffing shortages;

·Increasingly fast, sophisticated, expensive, and high-profile attacks target organizations of all sizes;

·Compliance and regulatory mandates;

·Heightened cybercrime activity among commercial enterprises and nation states;nation-states;

·Automation is increasingly considered critical to accelerating detection and protection; and

·The need to simplify operations through vendor consolidation.

 

These are some of the reasons why we believe Cyren’s vision for 100% cloud security is compelling to IT security teams looking to protect their businesses in today’s cloud-centric mobile-first world. 

 

Growing Our Enterprise Business

Cyren has prioritized growing its enterprise revenues. With the mid-2020 release of our anti-phishing solution, Cyren Inbox Security (CIS), we believe helping enterprises mitigate phishing attacks is our most significant revenue growth opportunity. Given the substantial size of the enterprise anti-phishing market, Cyren believes this new revenue stream has the potential to grow faster than our legacy OEM business. As this CIS business grows, it will gradually contribute to a larger portion of our overall revenue, and as a result, we expect deferred revenue to increase and our operating results and cash flow to improve.

Investments in Operations, Research and Development and Sales and Marketing

 

Our cost of revenues, research and development (“R&D”) expenses, and sales and marketing expenses are all significant contributing factors to our operating losses. Nonetheless, we expect to increase our investments in all three areas in order to grow our revenues. Over time, we expect that ourwe will increase utilization of our cloud infrastructure which we expect will increase and provide the opportunity for improved gross margins. Our investments in R&Dresearch and development are required in order to enhance and improve our solutions. In the future, we expect to lower the rate of R&D investment as a percentage of revenue, and we will be able to drive more revenue from existing solutions rather than by adding new solutions.revenue. The return on our sales and marketing investment is tied to attracting new customers and enhancing our business with existing customers, thereby lowering the overall sales and marketing costs as a percent of revenues. Finally,During 2020 we continuereduced our overall headcount in order to increase ourreduce expenses, and we believe managing future headcount to support the growth of the business, but we expect that reducing the historical rate of headcountand expense growth will be key in improving our gross and operating margins over time. In the third quarter of 2021, headcount remained consistent with the second quarter of 2021. Headcount on a year-over-year basis is down by about 10% which has led to a decline in operating expenses on a year-to-date basis compared to the corresponding period a year ago. We continue to monitor expenses and where possible, reduce expenses. We believe managing future headcount and expense growth will be key in improving our gross and operating margins over time given the recent decline in revenue.

  

Growing Our Enterprise SaaS Business

Although all of our services are subscription services, our Enterprise Security-as-a-Service offerings on the CCS platform are typically invoiced up front for an annual contract amount, or the full multi-year contract amount, at the start of the term. As a result, this business is expected to provide a larger immediate contribution to cash flow and better return on investment. As this enterprise business grows as a portion of our overall revenues, we expect to increase deferred revenue and our operating results and cash flow to improve, which will make us less reliant on other sources of capital in the future.

Components of our Operating Results

 

Revenue

 

We derive revenues from the sale of real-time cloud-based services for each of Cyren’s email security, web security, antimalware, and advanced threat protection offerings.

 

- 22 -

We sell all of our solutions as subscription services, either throughto OEMs and service providers which are considered Cyren customers, or as complete security services directly or indirectly via our partners, to enterprises.

 

-25-

Cost of RevenuesRevenue

 

Personnel costs, which consist of salaries, benefits, bonuses, and stock-based compensation for employees that operate our networkcloud infrastructure and provide support services to our customers, as well as data center costs, are the most significant components of our cost of revenues. Other costs include third partythird-party contractors, royalties for use of third partythird-party technologies, amortization of intangibles, and depreciation of data center equipment. We expect these costs to continue tomay increase in absolute dollars as we continue to invest in enhancingoptimize our cloud infrastructure and our support services.services, but should reduce as a percentage of overall revenue.

 

Operating Expenses

 

Our operating expenses consist of R&D,research and development, sales and marketing, and general and administrative expenses. Personnel costs, which consist of salaries, benefits, bonuses, and stock-based compensation, are the most significant component of our operating expenses. Operating expenses also include allocated overhead costs for facilities, IT, and depreciation. We expect operating expenses to increase in absolute dollars as we continue to grow.

 

Research and Development. R&D expense consistsResearch and development expenses consist primarily of personnel costs and outsourced engineering and threat analysis services. We believe these investments are crucial for our ability to continue to enhance the functionality of our services, as well as to develop and introduce new services to the market. We expect R&D expenses to continue increasing in absolute dollars as we continue to invest in our service offerings. Development costs related to internal use technology that supports our security services are capitalized on the balance sheet, while other development costs are expensed as they are incurred.

 

Sales and Marketing. Sales and marketing expenses primarily include personnel costs, sales commissions, marketing activities, and travel associated with sales and marketing. We market and sell our services worldwide through our sales organization and distribution channels. We capitalize sales commissions paid to internal sales personnel and amortize these expenses over an estimated period of benefit that reflects the expected future revenue streams. We expect ourreduced sales and marketing expenses to continuein 2020 but anticipate that we may need to increase investment in absolute dollars as we continuethese areas related to products newly launched in 2020 and enhance our sales and marketing teamsefforts to support our further growth. Our salesSales personnel are typically not immediately productive, and therefore the increase in expenses we incur when adding personnel is not immediately accompanied by increased revenue and in some cases may not result in increased revenue if these new sales personnel are unsuccessful in becoming productive.

 

General and Administrative.Administrative. General and administrative expenses consist primarily of personnel costs, audit fees, legal expenses, recruiting expenses, and other general operating costs. We expect our general and administrative expenses to continue to grow in absolute dollars as we continue our operational growth.

Other Income (Expense), net

 

Other income (expense), net consists primarilygenerally of capital gain or loss from the sale of assets.

 

Financial Expenses, net

 

Financial expenses, net consist mainly of foreign exchange gains and losses, interest expense on our outstanding debt, and interest income earned on our cash and cash equivalents. In 2020 and 2021, these expenses also included income related to the accounting for a multi-year arrangement where a customer paid upfront the full contract value. This has been deemed a significant financing component under ASC 606.

 

Tax Benefit

 

Our tax benefit is derived primarily from income taxes in foreign jurisdictions in which we conduct business. We estimate income taxes in each of the jurisdictions in which we operate. This process involves determining income tax expense together with calculating the deferred income tax expense related to temporary differences resulting from the differing treatment of items for tax and accounting purposes. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. These temporary differences result in deferred tax assets and liabilities, which are included net as applicable within our balance sheets. For most of our recent years, we have incurred operating losses in Israel and the U.S., where we have recorded a full valuation allowance against our deferred tax assets in those jurisdictions.

 

- 23 -

-26-

 

RESULTS OF OPERATIONS

 

The following table sets forth financial data for the three and nine months ended March 31, 2019September 30, 2021 and 2018:2020. Percentages may not add due to rounding.

 

  

 

Three months ended

March 31,

 
  2019  2018 
  Amount  % of Revenue  Amount  % of Revenue 
Revenues $9,655   100% $7,636   100%
Cost of revenues  4,000   41   3,382   44 
Gross profit  5,655   59   4,254   56 
Operating expenses:                
Research and development, net  4,177   43   3,355   44 
Sales and marketing  3,856   40   4,145   54 
General and administrative  2,432   25   2,038   27 
Total operating expenses  10,465   108   9,538   125 
Operating loss  (4,810)  (50)  (5,284)  (69)
Other income (loss), net  248   3   (2)  - 
Financial expenses, net  (53)  (1)  4   - 
Loss before taxes on income  (4,615)  (48)  (5,282)  (69)
Tax benefit  39   -   46   1 
Net loss $(4,576)  (47)% $(5,236)  (69)%
  Three months ended  Nine months ended 
  September 30  September 30 
  2021  %  2020  %  2021  %  2020  % 
  Unaudited  Unaudited  Unaudited  Unaudited 
                         
Revenues $7,461   100% $9,114   100% $23,827   100% $27,944   100%
Cost of revenues  3,732   50%  3,792   42%  11,332   48%  11,168   40%
                                 
Gross profit  3,729   50%  5,322   58%  12,495   52%  16,776   60%
                                 
Operating expenses:                                
                                 
Research and development, net  4,100   55%  4,769   52%  12,460   52%  12,264   44%
Sales and marketing  2,785   37%  2,942   32%  8,154   34%  9,123   33%
General and administrative  2,336   31%  2,302   25%  6,801   29%  6,992   25%
                                 
Total operating expenses  9,221   124%  10,013   110%  27,415   115%  28,379   102%
Operating loss  (5,492)  (74)%  (4,691)  (51)%  (14,920)  (63)%  (11,603)  (42)%
Other income (expense), net  5   0%  1   0%  (12)  0%  9   0%
Financial expense, net  (320)  (4)%  (235)  (3)%  (821)  (3)%  (757)  (3)%
                                 
Loss before taxes  (5,807)  (78)%  (4,925)  (54)%  (15,753)  (66)%  (12,351)  (44)%
Tax benefit  20   0%  33   0%  181   1%  94   0%
                                 
Net loss $(5,787)  (78)% $4,892   (54)% $(15,572)  (65)% $(12,257)  (44)%

 

-27-

Three Monthsand Nine months Ended March 31, 2019September 30, 2021 Compared to the Three Monthsand Nine months Ended March 31, 2018September 30, 2020

 

Revenues. Revenues increasedfor the three and nine months ended September 30, 2021 decreased $1.7 million, or 18%, and $4.1 million or 15%, respectively, as compared to the corresponding periods last year. The decrease was mainly driven by $2.0a contract reduction from our largest customer (as first disclosed in the Q3 2020 Form 10-Q), which was effective in Q2 2021 and is detailed in Note 6.b. The revenue impact of this contract reduction was $0.7 million from $7.7and $1.7 million for the three and nine months ended September 30, 2021, respectively. Customer renewals at lower values and churn, coupled with the end of life of several legacy Enterprise products during 2020 also contributed to the decline in revenue for the respective periods.

During the second quarter of 2020, the Company released two new products, Cyren Inbox Security and Threat InDepth. Since these product launches, the Company has signed numerous new customer contracts representing over $2.5 million in revenue, but due to the timing and ratable nature of the contracts, there was not a material amount of revenue recognized in the nine months of 2021.

Cost of Revenues. Cost of revenues for the three months ended March 31, 2018 to $9.7 million for the three months ended March 31, 2019, which represents a 26% year-over-year increase. The increase was primarily driven by contract expansions with two large Threat Intelligence customers which were signed during the second quarter of 2018, as well as new and upsell contracts in the enterprise business during the second half of 2018. These increases were offset by a small number of customer terminations in the Threat Intelligence and enterprise businesses, but overall contract renewal ratesSeptember 30, 2021 were consistent with prior periods.

the corresponding period last year. Cost of Revenues. Cost of revenuesrevenue for the nine months ended September 30, 2021 increased by $0.6$0.2 million from $3.4 million foror 1% as compared to the three months ended March 31, 2018 to $4.0 million for the three months ended March 31, 2019, which represents an 18% year-over-year increase. corresponding periods last year.

For the three months ended March 31, 2019September 30, 2021, cost of revenues represented 41%50% of revenue, compared to 44%42% during the prior year, and accordingly, gross margins for the period were 59%50% for the three months ended March 31, 2019September 30, 2021 compared to 56%58% for the same period in the prior year.

For the nine months ended September 30, 2021 cost of revenues represented 48% of revenue, compared to 40% during the prior year, and accordingly, gross margins for the period were 52% for the nine months ended September 30, 2021 compared to 60% for the same period in the prior year. The increase on a year-to-date basis is driven by an increase in costamortization of revenues is thecapitalized development expenses of $0.3 million as a result of continued investmentthe newest Enterprise products launched in Q2 2020, an increase in bonus and stock-based compensation expense of $0.2 million and $0.1 million in the use of consultants. Offsetting the overall increase was a decrease in payroll and related costs of approximately $0.1 million due to a decline employee headcount of 32 employees as of September 30, 2021 compared to 35 as of September 30, 2020. Additional decreases were related to $0.2 million in costs associated with our global network and data centers as well as additional payroll expensedepreciation associated with data center assets and $0.1 million associated with royalties due to the decline in our Supportrevenue.

Operating Expenses. Total operating expenses for the three and Operations groupsnine months ended September 30, 2021 decreased $0.8 million, or 8%, and $1.0 million or 3%, respectively, as compared to the priorcorresponding periods last year. During the period, there was a slight decrease in amortization of capitalized development

Operating expenses for the three months ended March 31, 2019September 30, 2021, represented 124% of revenue, compared to $0.8 million from $0.9 million during the prior year.

Operating Expenses. Overall operating expenses increased by $1.0 million from $9.5 million110% for the three months ended March 31, 2018 to $10.5 million forSeptember 30, 2020. For the threenine months ended March 31, 2019, which represents an increaseSeptember 30, 2021, operating expenses represented 115% of 10% year-over-year. Operating expenses for the quarter totaled 108% of quarterly revenue, compared to 125% of quarterly revenue a year ago.102% for the nine months ended September 30, 2020. The increasedecrease in operating expenses was primarily due to an increasea decrease in employee headcount, captured in cost of revenues and operating expenses, which totaled 272171 employees at the end of March 31, 2019,September 30, 2021, compared to 247191 employees at the end of March 31, 2018.September 30, 2020.

 

- 24 -

-28-

 

Research and Development, Net. R&D expense increased by $0.8Research and development expenses, net decreased $0.7 million, from $3.4 millionor 14% for the three months ended March 31, 2018September 30, 2021. For the nine months ended September 30, 2021, research and development expenses, net increased by $0.2 million or 2% as compared to $4.2 millionthe corresponding period last year. R&D expense, net for the three months ended March 31, 2019, which represents an increaseSeptember 30, 2021 represented 55% of 25%.revenue, compared to 52% a year ago. For the nine months ended September 30, 2021, R&D expense, for the quarternet represented 43%52% of revenue compared to 44% a year ago. The increase in R&D expense is primarily driven by increased employee headcount higher payroll and an increase in outsourced developmentwas 111 employees as of September 30, 2021 compared to the same period in 2018. Approximately $0.2 million118 as of the increase was the result of capitalizationSeptember 30, 2020.

Capitalization of technology development, which reduces overall R&D expenses. Capitalization of technology developmentexpenses, decreased from $0.9 millionto zero for the periodthree months ended March 31, 2018 to $0.7September 30, 2021 from $0.2 million for the three months ended March 31, 2019.September 30, 2020 primarily driven by the new product launch in the second quarter of 2020 which as a result, in subsequent quarters, the capitalization has declined, leading to higher R&D costs. This was offset by the one-time write-off of $0.7 million in Q3 2020 of a previously capitalized R&D project that did not reoccur in Q3 2021. The decrease in R&D expense, net is also driven by reduced employee headcount leading to lower payroll and related costs of $0.2 million.

 

Capitalization of technology development, which reduces expenses, decreased to $0.2 million for the nine months ended September 30, 2021 from $1.8 million for the nine months ended September 30, 2020 primarily driven by the new product launch in the second quarter of 2020 which as a result, in subsequent quarters, the capitalization has declined, leading to higher R&D costs. This was offset by the one-time write-off of $0.7 million in Q3 2020 of a previously capitalized R&D project that did not reoccur in Q3 2021. The decrease in R&D expense, net is also driven by reduced employee headcount leading to lower payroll and related costs of $0.5 million and a decrease in the use of outside services and consultants of $0.2 million.

Sales and Marketing. Sales and marketing expenses decreased by $0.3$0.2 million, (rounded) from $4.1 millionor 5% for the three months ended March 31, 2018,September 30, 2021 and decreased by $1.0 million, or 11%, for the nine months ended September 30, 2021, as compared to $3.9 millionthe corresponding periods last year. Sales and marketing expenses for the three months ended March 31, 2019, which representsSeptember 30, 2021 represented 37% of revenue, compared to 32% a decrease of 7%. Salesyear ago. For the nine months ended September 30, 2021, sales and marketing expenseexpenses represented 40%34% of revenue duringcompared to 33% a year ago.

For the three month period ending March 31, 2019months ended September 30, 2021 compared to 54% of revenue for the same period ending March 31, 2018. Thea year ago, the decrease in sales and marketing expense was primarily due to a reduction of overall sales and marketing headcount from 65 employees to 5933 employees at the end of the firstthird quarter 2019, as wellof 2021 compared to 41 employees at the end of the third quarter of 2020. The primary driver of the decline is due to payroll and related costs decreasing by $0.1 million as a reductionresult of the decrease in overall marketing spend related to advertising and industry trade shows.headcount.

 

For the nine months ended September 30, 2021 compared to the same period a year ago, the decrease in sales and marketing expense was due to a reduction of overall sales and marketing headcount to 33 employees at the end of the third quarter of 2021 compared to 41 employees at the end of the third quarter of 2020. Payroll and payroll-related costs decreased by $0.7 million, intangible asset amortization decreased by $0.1 million as an asset had been fully amortized in Q3 2020, travel and related costs decreased by $0.1 million, and allocated costs to sales and marketing decreased by $0.2 million due the decline in headcount. These decreases were offset by an increase in the use of outside services by $0.1 million to enhance our sales and marketing efforts to support the growth of our 2020 new product releases.

General and Administrative. General and administrative (“G&A”) expense increased by $0.4 million from $2.0 million(G&A) expenses for the three months ended March 31, 2018September 30, 2021 were consistent with the corresponding periods last year. For the nine months ended September 30, 2021, G&A expenses decreased by $0.2 million, or 3%, as compared to $2.4 millionthe corresponding periods last year. G&A expenses for the three months ended March 31, 2019, which represents an increaseSeptember 30, 2021 represented 31% of 19%.revenue, compared to 25% a year ago. G&A expense for the nine months ended September 30, 2021 represented 25%29% of revenue, for the first quarter of 2019, compared to 27% of revenue during25% a year ago.

For the first quarter of 2018. The increase in G&A expense is mainly due to an increase in recruiting costs, legal costs, and board-related expensesnine months ended September 30, 2021 compared to the first quartersame period a year ago, legal expenses increased by $0.3 million primarily due to additional legal work related to two capital raises in 2021 compared to only one in 2020. This increase was offset by a decrease in travel-related costs of 2018.$0.1 million due to COVID-19, a decrease in bad debt expense of $0.2 million due to improved customer collections, a $0.1 million decrease in Corporate & IT allocations due to the decline in headcount and a $0.1 million decrease due to the reduction in the use of certain outside services and consultants.

 

-29-

Other Income (Expense), Net. Other income, net for the three months ended March 31, 2019September 30, 2021 was $0.2$0.005 million comparedprimarily related to an expense of $0.0 milliona miscellaneous cash receipt. Other income, net for the three months ended March 31, 2018. During the first quarter, we reached a financial settlementSeptember 30, 2020 was $0.001 million with the former shareholders of eleven$0.001 million related to the legal dispute regardingproceeds on the amount and timingdisposal of fixed assets.

Other income, net for the earn-out paymentsnine months ended September 30, 2021 was an expense of $0.012 million primarily related to the acquisitiondisposal of eleven (the “eleven settlement”). Sincefixed assets associated with the financial settlementexit of an office lease of $0.017 million offset by a miscellaneous cash receipt of $0.005 million. Other income, net for the nine months ended September 30, 2020 was less than$0.009 million with $0.013 million of expense associated with the accrued interest anddisposal of fixed assets associated with the unpaid earn-out consideration on the Company’s balance sheet, the difference was reflected as otherexit of an office lease offset by income during the period. For additional information, please referof $0.021 million related to “Earn-Out Consideration” below and Note 3 of the consolidated financial statements included elsewhere in this quarterly report on Form 10-Q (the “Quarterly Report”).miscellaneous cash receipts.

 

Financial Expense, Net. Financial expenses, net, were consistent for the three months ended September 30, 2021 as compared to the corresponding periods last year. For the nine months ended September 30, 2021, financial expenses, net decreased by $0.06 million or 8%, as compared to the corresponding periods last year. For the nine months ended September 30, 2021, interest expenses increased by $57 thousand$0.06 million due to a full quarter of interest expense for the three months ended March 31, 2019, to $53 thousand from an income of $4 thousand as compared2021 due to the prior year, due mainly to an increase in interest expenses associated with the convertible notes issued in December 2018. For additional information, please refer to Note 4issuance of the consolidated financial statements included elsewhereConvertible Debentures on March 19, 2020 which resulted in this Quarterly Report. In addition, during the three months ended March 31, 2019 we also recorded a decreasepartial period of $53 thousandinterest expense in the expenses resulting from the effectfirst quarter of foreign currency exchange rate fluctuation.2020.

 

Effective Corporate Tax Rates

 

Corporate tax rates and real capital gains tax in Israel were 23% for the three months ended March 31, 2019September 30, 2021 and 2018.2020.

 

Our German subsidiary is subject to German tax at a consolidated rate of approximately 30%.

 

Other non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence.

 

We do not provide deferred tax liabilities when we intend to reinvest earnings of foreign subsidiaries indefinitely. As of March 31, 2019,September 30, 2021, there are no undistributed earnings of foreign subsidiaries. 

 

- 25 -

We may currently qualify as an “industrial company” within the definition of the Law for the Encouragement of Industry (Taxation) and, as such, we may be eligible for certain tax benefits, including, inter alia, special depreciation rates for machinery, equipment and buildings, amortization of patents, certain other intangible property rights and deduction of share issuance expenses.

 

-30-

Net Operating Loss Carry-Forwards

 

As of December 31, 2018, Cyren’s2020, Cyren Ltd.’s net operating loss carryforwards for tax purposes amounted to $80.1$102.0 million and capital loss carryforwards of $17.8 million which may be carried forward and offset against taxable income in the future, for an indefinite period.

 

As of December 31, 2018,2020, the U.S. subsidiary had net operating loss carryforwards of $40.3$40.7 million for federal tax purposes and $8.8$10.6 million for state tax purposes. These losses may offset any future U.S. taxable income of the U.S. subsidiary and will expire in the years 20192021 through 2038.2040. 

 

On December 24, 2017, a “change in the respective ownership” event occurred upon the completion of a tender offer of our ordinary shares by an entity controlled by funds affiliated with Warburg Pincus LLC (“Warburg Pincus”), and in accordance with the relevant provisions of the Internal Revenue Code 382 of 1986 and similar state provisions. Therefore, our utilization of U.S. net operating losses are subject to substantial annual limitations. Management believes that the annual limitations will result in the partial expiration of net operating losses before utilization.

Management currently believes that based upon its estimations for future taxable income, it is more likely than not that the deferred tax assets regarding the loss carryforwards will not be utilized in the foreseeable future. Thus, a valuation allowance was provided to reduce deferred tax assets to their realizable value.

LIQUIDITY AND CAPITAL RESOURCES

 

WeThe Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future and therefore, the Company intends to finance our operations primarily from ouroperating costs over the next twelve months through a combination of existing cash on hand, reducing operating spend, potentially divesting non-core assets, and future issuances of equity and/or debt securities. As of September 30, 2021, we had an accumulated deficit of $264.2 million, cash and cash equivalents and cash from operations. As of March 31, 2019 and December 31, 2018, we had approximately $12.4$17.9 million, and $17.6generated a year-to-date net loss of $15.6 million. We have incurred losses since inception and expect to continue to incur losses for the foreseeable future. Current assets amounted to approximately $24.3 million with current liabilities of approximately $25.3 million, resulting in negative working capital (defined as current assets minus current liabilities) of approximately $1.0 million. The current cash balance and historical trend of cash used in operations along with the maturity of the convertible notes in December 2021, lack of certainty regarding a future capital raise and our ability to renegotiate the term of the convertible notes, raise substantial doubt about our ability to continue as a going concern for the next twelve months from the date of issuance of this Form 10-Q. As the convertible notes mature in December 2021, the Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. If the restructuring discussions are not successful, the Company intends to use its available cash equivalents, respectively.resources to repay the principal upon maturity per the terms of the convertible notes. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences to our financial condition and results of operations.

 

Our future capital requirements will depend on many factors, including, but not limited to our growth, market acceptance of our offerings, the timing and extent of spending to support our efforts to develop our platform, and the expansion of sales and marketing activities. We may be required to seek additional equity or debt financing. In the event thatIf additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we issue additional equity securities to raise additional funds, further dilution to existing stockholders may occur. However, we cannot predict with certainty the outcome of our actions to generate liquidity, including the availability of additional financing. If we are unable to raise additional capital when desired, our business, financial condition, and results of operations could be adversely affected.

 

Please see the Financings section below for more details on the Company’s recent efforts to fund operating activities.

Outlook

 

During 2019, we expectOn July 8, 2021, the shareholders of the Company approved an increase in the number of authorized ordinary shares from 110,000,000 ordinary shares of nominal value NIS 0.15 per share to 160,000,000 ordinary shares of nominal value NIS 0.15 per share. The Company’s ability to continue as a going concern is dependent upon the Company growing the business, obtaining the necessary financing to meet its obligations, repay its liabilities arising from normal business operations, and the Company’s ability to gain compliance with the Nasdaq Capital Market listing standards (see Item 1A Risk Factors in the 2020Annual Report and Item 1A. Risk Factors in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 for additional information). The initial cure period ended on October 5, 2021. The Company received a 180-day extension in October 2021 to meet the minimum bid price requirement. The Company now has until April 4, 2022 to meet this requirement. The Company will continue to monitor the bid price for its ordinary shares and consider various options available to it if the ordinary shares do not trade at a level that is likely to regain compliance. These options include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the minimum bid price requirement or maintain compliance with any of the other Nasdaq continued listing requirements. The Company is currently negotiating to restructure the convertible notes with the noteholders and at this time is uncertain as to the outcome. The Company’s ability to raise additional equity is limited by the number of authorized shares available. While the Company intends to finance operating costs over the next twelve months through a combination of existing cash on hand, reducing operating spend, potentially divesting non-core assets, amending the terms of outstanding debt securities, and future issuances of equity and/or debt securities the Company cannot predict the availability of additional financing or the outcome of its actions to generate liquidity or regain compliance with the Nasdaq Capital Market listing standards.

Over the past several years, the Company has devoted most of its effort to research and development and increasing revenues through additional investments in sales and marketing. The Company generated a net loss of $15.6 million for the nine months ended September 30, 2021 and a negative cash flow of $12.5 million from operating activities for the nine months ended September 30, 2021. The Company has incurred losses since inception and expects to continue to incur capital expenditures associated with R&D and data center infrastructure.  We generated a loss of $4.6 million and negative cash flow of $1.3 million from operating activities inlosses for the three month period ended March 31, 2019, and have an accumulated deficit of $217.8 million as of March 31, 2019. We are planning to finance our operations from our existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However, there is no assurance that additional capital and/or financing will be available to us, and even if available, whether it will be on terms acceptable to us or in amounts required. Accordingly, our Board approved a contingency plan, to be effected if needed, in whole or in part, at its discretion, to allow us to continue our operations and meet our cash obligations. The contingency plan consists of cost reduction, which include mainly the following steps: reduction in consultants’ expenses, headcount, compensation paid to key management personnel and capital expenditures. We and the Board believe that our existing capital resources and other future measures that may be implemented, if so required, will be adequate to satisfy our expected liquidity requirements for at least twelve months from the filing date.foreseeable future. 

 

- 26 -

-31-

 

Cash Flows from Operating Activities

 

Cash used in operating activities was $12.5 million for the nine months ended September 30, 2021 as compared to $5.4 million for the nine months ended September 30, 2020.

For the nine months ended September 30, 2021, the primary factors affecting our operating cash flows during the period were our net loss of $15.6 million, adjusted for non-cash items of $1.8 million of stock-based compensation expense, $1.3 million for the three months ended March 31, 2019 as compared to $4.3amortization of our non-cash operating lease expense, $3.9 million for depreciation and amortization of our property, equipment, and intangible assets, $1.0 million for amortization of deferred commissions and $1.0 million associated with interest and amortization of debt issuance costs associated with our convertible notes and debentures. The primary drivers of the three months ended March 31, 2018. Thechanges in operating assets and liabilities were a $1.5 million decrease in cash usageoperating lease liabilities, a $0.8 million decrease in capitalization of $3.0deferred commissions, a $0.7 million was primarily due to a multi-year prepayment for services to be provided related to a customer contract renewal during the first quarter of 2019. The prepayment is reflected on the balance sheet asdecrease in prepaid expenses and other receivables, and offset by an increase in short-termtrade receivables of $2.9 million primarily driven by a delayed payment from a customer of $2.1 million which was received in October 2021.

For the nine months ended September 30, 2020, the factors affecting our operating cash flows during the period were our net loss of 12.3 million, adjusted for non-cash items of $1.9 million of stock-based compensation expense, $1.5 million for amortization of our operating lease right-of-use assets, $3.9 million for depreciation and long-termamortization of our property, equipment and intangible assets, and $1.2 million for amortization of deferred revenue.commissions. The primary drivers of the changes in operating assets and liabilities were an increase of $1.0 million in deferred revenue offset by a $1.5 million decrease in operating lease liabilities and a $0.9 million decrease in capitalization of deferred commissions.

 

Cash Flows from Investing Activities

 

CashFor the nine months ended September 30, 2021, net cash used in investing activities was $1.2$0.7 million which primarily consisted of $0.2 million for capitalization of technology and $0.5 million used to purchase property and equipment.

For the threenine months ended March 31, 2019 asSeptember 30, 2020, net cash used in investing activities was $2.6 million which primarily consisted of $1.1 million for capitalization of technology and $1.5 million used to purchase property and equipment.

Our capital expenditures over the past three years has consisted primarily of continued investment in R&D and purchases of property and equipment to modernize and expand our data centers and to invest in our infrastructure to support new products and to facilitate the growth of the Company.

Capitalization of technology has decreased in 2021 compared to $1.5 million for the three months ended March 31, 2018. The decrease of $0.3 million was2020 primarily due to a decreasethe new products launched in capital expenditures compared to the same period a year ago.first half of 2020.

 

Cash Flows from Financing Activities

 

Cash used inFor the nine months ended September 30, 2021, net cash generated by financing activities was $2.5$21.9 million as we issued to several institutional investors in February 2021 in a registered direct offering (the “Offering”) 12,000,000 of our ordinary shares at a purchase price of $1.15 per share for net proceeds of approximately $12.6 million. In September 2021, we issued 14,152,779 ordinary shares to certain institutional investors at a purchase from of $0.72 per share for net proceeds of approximately $9.3 million.

For the threenine months ended September 30, 2020, net cash generated by financing activities was $9.4 million which was attributable to the Convertible Debentures issued on March 31, 2019 as compared to $0.019, 2020 with gross proceeds of $10.2 million, foroffset by the three months ended March 31, 2018. The increase of $2.5 million was primarily due to a payment of $2.7 million in conjunction with the eleven settlement. The eleven settlement was offset by $0.2 million generated from the exercisedebt issuance costs of stock options in the period.$0.8 million.

 

Working Capital

 

As of March 31, 2019September 30, 2021, we had negative working capital of $1.0 million and 2018,as of September 30, 2020, we had positive working capital of $5.1 million and $7.7 million, respectively.$0.4 million. The decrease in working capital during the three months ended March 31, 2019 asin 2021 compared to 2020 was driven by the prior year is primarily$10.0 million convertible notes which are due December 2021 and as a result, are presented in current liabilities as of September 30, 2021, compared to long-term liabilities as of September 30, 2020 and offset by a higher cash balance as of September 30, 2021 compared to September 30, 2020 due to our negative cash flow from operations and lower amounts ofthe capital raised during the fourth quarter of 2018 compared to amounts of capital raised during the fourth quarter of 2017.raise noted above in September 2021.

-32-

 

Convertible NotesFinancings

On December 5, 2018, wethe Company issued an aggregate $10.0 million aggregate principal amount of convertible notes in a private placement (the “Notes”) to affiliates of an existing minority institutional shareholder. The Notesconvertible notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The Notesnotes have a 3-year term and mature in December 2021, unless converted in accordance with their terms prior to maturity. The Notes havenotes were issued with a conversion price of $3.90 per share which may bewas subject to adjustment using a weighted averageweighted-average ratchet mechanism based on the size and price of future capital raisesequity offerings and the total shares outstanding. We are currently negotiating to restructure the convertible notes with the noteholders to postpone the final repayment date by several months under certain terms, although there is no assurance that we will be able to do so on commercially reasonable terms or at all. If the restructuring discussions are not successful, the Company intends to use its available cash resources to repay the principal upon maturity per the terms of the convertible notes.

On November 7, 2019, we completed a rights offering that raised gross proceeds of $8.0 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. In addition, the Notes would beconvertible notes are subject to immediate conversion upon any change in control in the Company.Company (or subject to repayment if the price in the change in control transaction is less than the conversion price).

Earn-Out Consideration

In conjunctionOn March 19, 2020, we issued $10.25 million aggregate principal amount of Convertible Debentures in a private placement to certain investors. The Convertible Debentures are secured by a guarantee by two of our subsidiaries and carry a 5.75% interest rate, payable semi-annually in cash or, subject to the satisfaction of certain equity conditions, in ordinary shares. The Convertible Debentures mature in March 2024, unless converted in accordance with their terms prior to maturity. The Convertible Debentures have an initial conversion price of $0.75 per share, subject to adjustments. If the 2012 acquisitionclosing bid price of eleven,our ordinary shares has been at least $2.25 (subject to adjustment) for at least 20 trading days during any 30 consecutive trading day period, and certain conditions are satisfied, we entered into an earn-out agreement with the former shareholders that would pay additional consideration based on the revenue performance for the years ending 2012-2015. Subsequently in 2014, we hadmay force a legal dispute regarding the amount and timingconversion of all or any part of the earn-out paymentsoutstanding principal amount of the Convertible Debentures, accrued and had entered into arbitral proceedings withunpaid interest and any other amounts then owing, subject to certain conditions.

On February 16, 2021, we issued to several institutional investors in a registered direct offering, 12,000,000 of our Ordinary Shares at a purchase price of $1.15 per share for net proceeds of approximately $12.6 million. We intend to use the former shareholdersproceeds from this offering for working capital and general corporate purposes. As a result of eleven. On March 9, 2017, we receivedthis offering, the arbitral judgement. Pursuantconversion price of the convertible notes was adjusted to $3.38.

We also issued to the judgement, the earn-out consideration balance was increasedplacement agent or its designees warrants to reflect additional legal expenses and interest expenses covering the periodpurchase up to December 31, 2016. During 2017 and 2018, we continued to accrue interest on720,000 ordinary shares, representing 6% of the unpaid earn-out consideration balance. Such interest is reflectedaggregate number of ordinary shares sold in the consolidated statements of operations under financial expenses, net. In May 2018, we made a partial paymentoffering. The placement agent warrants have an exercise price equal to $1.4375, or 125% of the earn-out consideration tooffering price, per Ordinary Share and became exercisable on August 16, 2021 for five years from the effective date of the six former shareholders,offering.

On September 17, 2021, we issued to several institutional investors in a private placement, 14,152,799 of our ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an amountexercise price of $0.6 million.$0.60 per share. The earn-out consideration balance presentedwarrants will be exercisable immediately and terminate on our balance sheet asMarch 17, 2025. As a result of December 31, 2018 reflectedthis offering, the complete remaining liability relatingconversion price of the convertible notes was adjusted to $3.02.

We also issued to the earn-out, including accrued interest. In February 2019, the parties agreedplacement agent or its designees warrants to resolve all pending claims, and on February 28, 2019, we paid approximately $2.7 millionpurchase up to settle the earn-out consideration in full. For additional information, please refer to Note 3849,167 ordinary shares, representing 6.0% of the consolidated financial statements included elsewhereaggregate number of ordinary shares sold in this Quarterly Report.the offering. The placement agent warrants have an exercise price equal to $0.90 per share, or 125% of the offering price per share and were exercisable immediately and terminate on March 17, 2025.

 

- 27 -

-33-

Registration Statements

 

In connection with a previously disclosedour private placement to Warburg Pincus in November 2017, in which we issued approximately 10.6 million ordinary shares to an entity controlled by funds affiliated with Warburg Pincus,for $1.85 per share, we and Warburg Pincus entered into a registration rights agreement, which, among other things, provides Warburg Pincus with three demand registration rights, piggyback and shelf registration rights. The demand registration rights may be exercised startingbecame exercisable as of August 6, 2018, subject to certain customary blackout periods.

In addition, asconnection with the issuance of November 6, 2019, at the request of Warburg Pincus,Convertible Debentures, we will be requiredentered into a registration rights agreement with the purchasers. Pursuant to filethat agreement, we filed a shelf registration statement on Form S-3 with the SEC covering the saleresale of Warburg Pincus’s shares.our ordinary shares that are issuable to the purchasers upon any conversion of the Convertible Debentures or as interest payments.

 

On September 21, 2018, we filed a shelf registration statement on Form F-3 with the Securities and Exchange Commission (“SEC”),SEC, which we intend to convertconverted to a Form S-3 during the second quarter ofon August 16, 2019. This registration statement enabledenables us to issue debt securities, ordinary shares, warrants, or subscription rights up to an aggregate amount of $50 million. Under the rules governing shelf registration statements, once we convert the registration statement on Form F-3 to a registration statement on Form S-3, we will thereafter be able to file a prospectus supplement with the SEC which describes the amount and type of securities being offered each time we issue securities under thethis registration statement. No securities were issued under the registration statement on Form F-3 from September 21, 2018 throughF-3. In November 2019, we issued shares as part of our rights offerings, and in February 2021, we issued shares in the dateregistered direct offering using our Form S-3 as described above.

On October 1, 2021, as a part of the filingprivate placement noted above in September 2021, we a filed shelf registration statement on Form S-3 with the SEC. This registration registered 29,154,725 ordinary shares, consisting of this Quarterly Report.(i) 14,152,779 ordinary shares, (ii) 14,152,779 ordinary shares issuable upon the exercise of warrants issued in a private placement described above, and (iii) 849,167 ordinary shares issuable upon exercise of the placement agent warrants issued in a private placement described above.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2019,September 30, 2021, we did not have any off-balance sheet arrangements. 

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies are discussed in Note 2. Significant Accounting Policies to our consolidated financial statements included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2019.2020 Annual Report. There have been no significant changes to these policies for the three months ended March 31, 2019,September 30, 2021, except as described in Note 2. Significant Accounting Policies to our condensed consolidated financial statements are included elsewhere in this Quarterly Report. The critical accounting policies requiring estimates, assumptions, and judgementsjudgments that we believe have the most significant impact on our consolidated financial statements are described in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 20182020 Annual Report.

 

Recent Accounting Pronouncements

 

Please refer to Note 2. Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a full description of recent accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

Special Note Regarding Forward-Looking Statements

 

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements concern expectations, beliefs, projections, plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. We urge you to consider that statements which use the terms “anticipate,” “believe,” “expect,” “plan,” “intend,” “estimate”, “will” and similar expressions are intended to identify forward-looking statements. Specifically, this Quarterly Report contains forward-looking statements regarding:

 

·our expectations that our utilization of our cloud infrastructure will increase and provide an opportunity for improved gross margins;

our expectations regarding increases in cost ofour partnership with Microsoft;

our expectations regarding our future profitability and revenue and operatinggrowth;

our expectations that R&D expenses includingmay increase as a result of our anticipated investments in R&D;we enhance newly released products from 2020;

·our beliefs regarding the importance of R&D;

- 28 -
 

·our expectation to lower the rate of R&D investment as a percentage of revenue in the future and to drive more revenue from existing solutions rather than by adding new solutions;

-34-

·our expectations regarding reducing the historical rate of headcount growth and its resulting impact on our gross and operating margins over time;

·our expectations regarding our business strategies, including our contingency plan;
·our expectations regarding growth of our enterprise business and its expected impact on our business, and operating results, including its contribution to our cash flow and return on investment;

·our expectations regarding our capital expenditures for 2019;2021;

·our belief regarding the adequacy of our existing capital resources and other future measures to satisfy our expected liquidity requirements;

·our anticipated increasesexpectations regarding trends in investments to grow our revenue;the market for internet security and technology industry; and

·our beliefs and expectations regarding existing and new threats, key challenges and opportunities in our industry, and their impact on our business;
·our expectations regarding the increase in utilization of our cloud infrastructure and the resulting impact on our gross margins;
·our beliefs regarding factors that make our vision compelling to the IT security market;
·our intention to convert our registration statement on Form F-3 to a registration statement on Form S-3;
·our beliefs regarding our net operating loss carry-forwards; and
·our expectations and estimates regarding certain tax and accounting matters,business, including the impact on our financial statements.of innovations in the technology industry.

 

These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties, and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important factors that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not limited to, the following:

 

·our ability to continue as a going concern;

our ability to restructure or refinance our convertible notes;

our ability to execute our business strategies;strategies, including our sales and business development plan;

·our ability to timely and successfully enhance and improve our existing solutions and introduce our new solutions;

the commercial success of such enhancements and new solutions;

lack of demand for our solutions, including as a result of actual or perceived decreases in levels of advanced cyber attacks;

·our ability to manage our cost structure, avoid unanticipated liabilities and achieve profitability;

·our ability to grow our revenues, including the ability of existing solutions to drive sufficient revenue;

·our ability to attract new customers and increase revenue from existing customers;

·market acceptance of our existing and new product offerings;

·the success of our partnership with Microsoft;

our ability to adapt to changing technological requirements and shifting preferences of our customers and their users;

·the impact of the COVID-19 outbreak;

our continued listing on Nasdaq;

-35-

loss of any of our large customers;

·adverse conditions in the national and global financial markets;

·the impact of currency fluctuations;

·political and other conditions in Israel, Germany, and Iceland that may limit our R&D activities;
increased competition or our ability to anticipate or effectively react to competitive challenges;

·the ability of our brand development strategies to enhance our brand awareness;

our ability to retain key personnel;

performance of our OEM partners, service providers, and resellers;

our ability to successfully implement our contingency plan, if needed,estimate the impact of regulatory and its ability to allow us to continue our operations and meet our cash obligations;litigation matters;

·our ability to comply with applicable laws and regulations and the impact of changes in applicable laws and regulations, including tax legislation or policies;

·economic, regulatory, and political risks associated with our international operations;

·the impact of cyber attacks or a security breach of our systems;

our ability to protect our brand name and intellectual property rights;

the impact of our controlling shareholder’s decisions, which may differ with respect to our strategic direction;and

·our ability to successfully estimate the impact of certain accounting and tax matters, including the effect on our company of adopting certain accounting pronouncements.

 

- 29 -

-36-

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by usthe Company (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by us.the Company. Please refer to the factors described in Part II. Item 1A. Risk Factors in the Quarterly Report for the quarterly period ended March 31, 2021 and Part I. Item 1A. Risk Factors, of our 2018the 2020 Annual Report for additional information regarding factors that could affect our results of operations, financial condition, and liquidity. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof.

 

Impact from the COVID-19 Outbreak

On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic” which is now known as COVID-19. The outbreak has impacted thousands of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations.

As of the date of issuance of the financial statements, the Company’s operations have not been significantly impacted, however, the Company continues to monitor the situation. The ultimate extent of the impact of any epidemic, pandemic, or other health crisis on our business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic or other health crisis and actions taken to contain or prevent their further spread, among others.

No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of quarter-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future.

In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time.

ITEM 4. CONTROLS AND PROCEDURES

 

Management’s Evaluation of Disclosure Controls and Procedures

In order to ensure that the information we must disclose in our filings with the SEC is recorded, processed, summarized, and reported on a timely basis, we have formalized our disclosure controls and procedures. Our principal executive officer and principal financial officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Securities and Exchange Act Rules 13a-15(e) and 15d-15(e) as of March 31, 2019.September 30, 2021. Based on such evaluation, such officers have concluded that, as of March 31, 2019,September 30, 2021, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting, as defined in Securities and Exchange Act Rules 13a-15(f) and 15d-15(f), that occurred during the quarter ended March 31, 2019September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

-37-

PART II – OTHER INFORMATION.

ITEM 6. EXHIBITS

 

Exhibit No.Description of Exhibits
31.14.2Amended and Restated Articles of Association, as amended on September 9, 2021 (incorporated by reference to Exhibit 4.2 to the Form S-3 (File No. 333-259959) filed on October 1, 2021.
31.1Certification by Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 20022002..
31.2Certification by Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 20022002..
32.1Certification by Chief Executive Officer and Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 20022002..
101.INSXBRL Instance Document.Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File – the cover page iXBRL tags are embedded within the Inline XBRL document.

 

- 30 -

-38-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 CYREN LTD.
  
MayNovember 15, 20192021/s/ Brett Jackson
 Brett Jackson

Chief Executive Officer
 (Duly Authorized Officer)

 

November 15, 2021
May 15, 2019/s/J. Michael Myshrall Kenneth Tarpey
 J. Michael Myshrall
Kenneth Tarpey
Chief Financial Officer
 (Principal Financial Officer)

 

-39-

- 31 -

iso4217:USD xbrli:shares